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1. ABSTRACT 
 
Bovine mastitis caused by Escherichia coli remains a problem in many countries despite of 
improvements in managing and housing of dairy cattle. Cows with compromised immune systems, 
especially those in early lactation, are particularly susceptible to E. coli intramammary infection. 
Mastitis caused by E. coli varies from mild,  with local signs only,  to severe systemic.  The severe 
form of E. coli mastitis is associated with loss of milk production and can result in death of the cow. 
Intramammary infection caused by E. coli is often eliminated spontaneously as the defense 
mechanisms of the cow are able to clear the bacteria from the udder. The aims of this thesis were to 
investigate host response to E. coli mastitis in terms of characteristics of bacteria, effect of 
antimicrobial and non-antimicrobial treatment, and prophylactic effect of recombinant human 
lactoferrin expressed in milk. 
 
Host response was studied using two consecutive intramammary challenges with E. coli in the same 
cows at a short interval. All cows became infected, but local signs were significantly milder and 
disappeared faster after the second challenge. The same pattern was recorded for the indicators of 
inflammation; the differences being statistically significant for serum and milk haptoglobin, milk 
serum amyloid A, and white blood cell count. Milk production returned to the pre-challenge level 
significantly faster after the second challenge. This study revealed a possible carry-over or 
immunizing effect of the previous intramammary infection by the same pathogen. 
 
Broad-spectrum antimicrobials have been widely used for treating E. coli mastitis, although the 
results  of  treatment  studies  have  been  controversial.  In  our  field  study,  systemic  enrofloxacin  
treatment did not result in better bacteriological or clinical cure of acute clinical mastitis caused by 
E. coli than supportive treatment alone. Enrofloxacin treatment did not affect survival of the cows, 
return of quarter milk production or tissue damage of the affected quarter within three weeks post-
treatment; nor did it affect the length of time the cow remained in the herd during the six-month 
follow-up period. The only positive effect of the enrofloxacin treatment was a higher bacteriological 
cure 2 days post-treatment.  On the contrary,  clinical  cure on day 2 was lower in the enrofloxacin 
treated cows. Clinical cure assessed 21 days post-treatment was relatively low in both groups, 
which probably reflects the severe nature of acute E. coli mastitis. Our study did not support the use 
of parenteral antimicrobial treatment of clinical E. coli mastitis. In severe cases of coliform mastitis, 
antimicrobial treatment could, however, still be recommended for safety reasons, as it can increase 
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the elimination of bacteria and prevent possible bacteraemia. Our results indicated also that frequent 
milking at the acute stage of mastitis might improve the initial clinical cure of E. coli mastitis and 
decrease inflammation and tissue damage in the infected quarter. 
 
Most E. coli isolates belonged to the phylogenetic group A, indicating their commensal nature. 
Close to 40% of the isolates had at least one virulence gene, but combinations of virulence genes 
varied greatly, each combination being present mainly in a single isolate. Approximately 30% of the 
isolates showed resistance to one or more antimicrobials tested, most commonly against ampicillin, 
streptomycin, tetracycline and sulphonamides.   No specific virulence factor, phylogenetic group or 
resistance to antimicrobials was associated with persistence or severity of disease among mastitis E. 
coli isolates in our field study. These results indicate that characteristics of bacteria are not likely to 
affect the clinical course and outcome of E. coli mastitis. In 11% of mastitis cases, the same 
genotype of E. coli was isolated from the affected quarter three weeks post-treatment as originally, 
indicating persistence of the same genotype of E. coli in the quarter.  
 
Non-antimicrobial treatments, such as lactoferrin, which has antibacterial and lipopolysaccharide 
neutralizing properties, could be beneficial in the treatment of E. coli mastitis. The efficacy of 
intramammary lactoferrin was compared with that of systemic enrofloxacin in an experimentally 
induced E.  coli model. No significant differences were found in the clinical signs between cows 
treated with lactoferrin and those treated with enrofloxacin. The results from this study remained 
inconclusive. The prophylactic effect of lactoferrin against E. coli mastitis was studied in a new 
model of using hLf-transgenic cows, which expressed recombinant human lactoferrin in their milk. 
This was the first study to describe an experimentally induced E. coli mastitis model using 
transgenic cows. The high concentration of lactoferrin in the milk of the transgenic cows did not 
protect the cows from E. coli intramammary infection, and all of them became infected. No 
differences were noted in the bacterial growth, times to bacterial elimination, clinical signs or in any 
of the milk or blood inflammatory parameters, except in concentrations of haptoglobin and cortisol 
in the serum. 
 
Prevention of E. coli mastitis relies on decreasing the infection pressure in the environment of the 
cows and improving the cow comfort and herd management. In E. coli mastitis, the treatment 
should be as efficient as possible, but novel therapeutic approaches are needed, as the efficacy of 
the current commonly used antimicrobial treatments is not satisfactory.       
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3. ABBREVIATIONS 
 
afa8 afimbrial adhesin AFA8 
APP acute phase proteins 
APR acute phase response 
AFOS serum alanine aminofosfatase 
ALAT serum alanine aminotransferase 
ASAT serum aspartate aminotransferase 
astA enteroaggregative heat-stable toxin 
bLf bovine lactoferrin 
cfu colony forming units 
CMT California Mastitis Test 
CNF1 cytotoxic necrotizing factor 1 
CNF2 cytotoxic necrotizing factor 2 
Cva colisin V plasmid 
DIM days in milk 
eaeA intimin 
ehxA enterohemolysin 
ELISA enzyme-linked immunosorbent assay 
ESBL extended spectrum beta-lactamase 
f17A F17 fimbria 
hLf human lactoferrin 
Hp haptoglobin 
irp2 yersinia bactin 
iss increased serum survival 
iucD aerobactin 
LBP lipopolysaccharide binding protein 
LPS lipolysaccharide 
Lf lactoferrin 
MIC minimum inhibitory concentration 
NAGase N-acetyl-β-D-glucosaminidase 
NSAID non-steroidal anti-inflammatory drugs 
papC P-fimbria 
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PCR polymerase chain reaction 
PCV packed cell volume 
PC postchallenge 
PMN polymorphonuclear leucocytes 
rhLf recombinant human lactoferin 
SAA serum amyloid A 
Saa autoagglutinating adhesin 
SCC somatic cell count 
SEM standard error of the mean 
sfaD S-fimbria 
stx1 shigatoxin 1 
stx2 shigatoxin 2 
TNF-α tumor necrosis factor alpha 
Tsh temperature-sensitive hemagglutinin 
Vat vacuolating autotransporter protein 
WBC white blood cell 
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4. INTRODUCTION  
 
Escherichia coli is among the most common infectious agents isolated from severe mastitis cases in 
modern dairy farms (Hogan et al., 1989; Bradley et al., 2007). E. coli has been reported to be the 
most common cause of clinical mastitis in well-managed dairy herds with low milk somatic cell 
counts (SCC) in the United Kingdom (Bradley 2002). In Finland, E. coli has been isolated in 6% of 
quarter milk samples taken from clinical mastitis cases, more frequently in spring and summer 
(Koivula et al., 2007). Clinical E. coli mastitis can range from mild with only local signs to severe 
disease  with  systemic  clinical  signs.  In  severe  cases  the  outcome can  be  acute  tissue  damage  and  
complete loss of milk production or even the death of the diseased cow (Golodetz et al., 1983; 
Shuster et al., 1996; Shpigel et al., 1997). 
 
Cows in early lactation are reported to be more susceptible to E. coli mastitis (Hill et al., 1978; Hill 
et al., 1979; Pyörälä and Pyörälä, 1998). This has been shown to result from decreased neutrophil 
function (Kehrli et al., 1989; Mehrzad et al., 2002), delayed neutrophil migration to the mammary 
gland (Hill et al., 1979; Kehrli et al., 1989; Shuster et al., 1996; Vandeputte-Van Messom et al., 
1993) and faster growth of bacteria in the mammary gland of early-lactating cows (Shuster et al., 
1996). 
 
Factors that are cow-dependent, like the speed of the inflammatory response, lactation stage and age 
of the cow, are thought to determine the severity of E. coli mastitis (Burvenich et al., 2003). The 
role of specific bacterial features, such as virulence factors, has been considered to be small. The 
only virulence factor of E. coli associated with bovine mastitis is serum resistance (Carrol and 
Jasper, 1977; Sanchez-Carlo et al., 1984; Fang and Pyörälä, 1996). A variety of different virulence 
factors, individually and in combinations, has been detected in E. coli isolates that cause mastitis 
(Nemeth et al., 1991; Nemeth et al., 1994; Lipman et al., 1995; Kaipainen et al., 2002). However, 
the most mastitis isolates have not possessed any of the virulence factors evaluated (Sanchez-Carlo 
et al., 1984; Nemeth et al., 1991; Kaipainen et al., 2002; Wenz et al., 2006). 
 
Broad-spectrum antimicrobials are commonly used systemically or as an intramammary in the 
treatment of acute E. coli mastitis (Erskine et al., 2003). However, results of the treatment studies 
have  been  controversial.  No  difference  was  established  between  groups  treated  with  or  without  
antimicrobials in experimentally induced E. coli mastitis (Erskine et al., 1992; Pyörälä et al., 1994), 
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while other studies reported some benefits of antimicrobial treatment (Shpigel et al., 1997; Rantala 
et al., 2002; Poutrel et al., 2008). Parenteral administration of broad-spectrum antimicrobials has 
been recommended for the treatment of severe coliform mastitis, due to the risk of bacteremia 
(Cebra et al., 1996; Wenz et al., 2001b). Broad-spectrum antimicrobials, commonly used for 
mastitis treatment, are of major therapeutic importance also in human medicine, and their broad use 
in food-producing animals has stimulated public health concerns (Collignon et al., 2009). 
 
Non-antimicrobial approaches for treating of E. coli mastitis have been studied as alternatives to 
antimicrobials. Non-steroidal anti-inflammatory drugs (NSAID), frequent milking and fluid therapy 
have been commonly recommended for supportive treatment of coliform mastitis (Radostits et al., 
2007). Correction of dehydration with fluid therapy is usually indicated in severe cases. Other non-
antimicrobial approaches, such as recombinant bovine soluble CD14 (Lee et al., 2003) and 
lactoferrin (Lf), an antibacterial glycoprotein present in milk (Komine et al., 2006; Lacasse et al., 
2008), have also been tested for treating of bovine mastitis. 
 
Prevention of E. coli mastitis relies on limiting the exposure of the udder to Gram-negative bacteria 
from the barn environment. One of the primary sources of bacterial contamination is bedding 
contaminated with manure. Management practices that reduce the number of bacteria in the 
environment of the cow generally decrease the occurrence of clinical mastitis caused by Gram-
negative bacteria (Hogan and Smith 2003). Measures that have been found to be successful for 
decreasing mastitis caused by contagious pathogens, such as post-milking dipping of teats with 
antiseptic agents, have failed to protect against coliform mastitis (Pankey et al., 1984). Vaccination 
by Gram-negative core antigen vaccines has been used for many years in North America and is now 
also available in Europe. The effect of vaccination is of short-duration and does not generally 
protect the cow from clinical mastitis, but does decrease the severity of clinical signs (Erskine et al., 
2007; Wilson et al., 2009). Genetic manipulation of dairy cows, to express recombinant 
immunomodulating proteins in their milk, would be one approach to mastitis prevention (Bramley 
et al., 2001; Oliver 2005; Wall et al., 2005). 
 
Mastitis control in modern dairy herds relies on prevention rather than treatment. Efficient treatment 
of clinical cases is, nonetheless, a component of the mastitis control programme. For the dairy 
farmer and for the veterinary practitioner it is critical that efficient treatments for severe cases of E. 
coli mastitis become available. Treatment should be economical and pose a minimal risk for 
residues in milk destined for human consumption. In practice, E. coli mastitis is usually detected 
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based on clinical signs, when bacterial counts in the milk are already high and tissue damage is 
already evident.         
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5. REVIEW OF THE LITERATURE 
 
5.1. CHARACTERISTICS OF ESCHERICHIA COLI  
5.1.1. Role of lipopolysaccharide 
E. coli is a member of the Enterobacteriacea family.  It  is  Gram-negative rod and able to ferment 
lactose. Bacterial lipopolysaccharide (LPS), also termed endotoxin, occurs in the outer membrane 
of the cell wall of Gram-negative bacteria, which comprises lipid-A, a lipopolysaccharide core and 
polysaccharide units (O-antigens) (Cullor 1996). Lipid-A is responsible for the toxic effects of LPS 
(Cullor 1996). LPS is considered to be a primary virulence factor of E. coli and responsible for most 
pathophysiological reactions in E. coli mastitis (Hogan and Smith 2003; Burvenich et al., 2003). It 
is released from the bacteria following cell death due to an inflammatory response and during 
bacterial multiplication (Burvenich et al., 2003). The local and systemic signs are induced by LPS 
and the subsequent release of inflammatory mediators (Lohuis et al., 1988a; Burvenich et al., 2003). 
However, LPS is sufficient, but may not be an essential factor in eliciting mastitis by E. coli (Gonen 
et al., 2007), indicating that also additional bacterial factors may be involved (Shpigel et al., 2008). 
 
LPS triggers formation of proinflammatory and inflammatory cytokines, produced predominantly 
by monocytes and macrophages (Henderson et al., 1996; Persson Waller et al., 2003). The cellular 
receptor  for  LPS  is  CD14,  which  mainly  occurs  on  monocytes  and  macrophages,  and  to  a  lesser  
extent on neutrophils (Paape et al., 2003). It facilitates recognition of LPS by the TLR4 receptor. 
Macrophages, dendritic cells and epithelial cells are expected to express TLR4 in the mammary 
gland (Werling et al., 2006; Gonen et al., 2007). Cytokines, such as tumor necrosis factor alpha 
(TNF-α), initiate the inflammatory response, which induces the acute phase response (APR) by 
activating the production of acute phase proteins (APP), such as serum amyloid A (SAA), 
haptoglobin (Hp) and LPS-binding protein (LBP) (Bannerman et al., 2003; Bannerman et al., 2004; 
Eckersall et al., 2001; Hirvonen et al., 1996; Hiss et al., 2004). 
 
5.1.2. Other virulence factors  
Pathogenic E. coli bacteria are typically associated with a specific disease and have specific 
virulence factors that contribute to their ability to cause infection, i.e. to colonize, multiply and 
survive under particular conditions, such as in the urinary track (UPEC pathotype) or in the intestine 
(EHEC and EPEC pathotype)  (China and Goffaux, 1999; Kaper et al., 2004). The major groups of 
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virulence factors of E. coli comprise  adhesins,  which  help  the  bacteria  to  adhere  to  and  colonize  
mucosal surfaces, and toxins, which are proteins with the ability to disturb or modify the normal 
function  of  the  host  cell  and  to  help  the  bacteria  to  cross  the  epithelial  barrier  and  to  invade  the  
tissue (China and Goffaux, 1999; Kaper et al., 2004). Other factors, like siderophores, which help 
bacteria to chelate iron, and factors that confer serum resistance, also contributed to bacterial 
virulence (Hirsh et al., 1993, Hogan and Smith, 2003). Most of the pathogenic E. coli possesses 
several kinds of pathogenic mechanisms and virulence factors (Kaper et al., 2004).   
 
There is substantial genotypic variability among E. coli strains that cause clinical mastitis. Previous 
studies on E. coli isolated from bovine mastitis reported that most of the isolates were serum 
resistant (Carrol and Jasper, 1977; Nemeth et al., 1991; Fang and Pyörälä, 1996). Different 
virulence factors, singly and in combinations, were detected, but most strains did not carry any of 
the virulence genes evaluated (Nemeth et al., 1991; Nemeth 1994; Lipman et al., 1995; Kaipainen et 
al., 2002). No specific virulence factors or pathotypes were found for expressing special ability to 
induce mastitis among E. coli isolated from mastitis (Kaipainen et al., 2002). No association 
between any virulence factors and severity of mastitis has been reported (Lehtolainen et al., 2003a; 
Wenz et al., 2006).  
 
5.1.3. Antimicrobial susceptibility 
Antimicrobial susceptibility of E. coli isolated from mastitis has been studied, but the results vary 
greatly according to the methods and breakpoints used. During the national monitoring of 
antimicrobial resistance of pathogens isolated from animals in Finland in 2005-2006, 9% of E. coli 
isolates were resistant to streptomycin, 7% to ampicillin, 7% to sulfametoxazole and 5% to 
tetracycline (FINRES-Vet 2005-2006). Resistance percentages were similar to those reported for E. 
coli isolated from clinical mastitis in Finland during 1990-1996 (Lehtolainen et al., 2003b). The 
proportions of resistant E. coli isolates in Finland were lower than those reported in the Netherlands 
(MARAN 2007), and much lower than those in France (AFFSA 2006). 
 
Many of the genes coding for antimicrobial resistance, as well as some virulence factors, are located 
in plasmids, and can be linked (Bagg et al., 1987; Martínez and Baquero, 2002). Use of 
antimicrobials may therefore influence the selection of virulence factors in bacteria (Hirsh et al., 
1993; Martínez and Baquero, 2002). 
 
 16
5.2. E. COLI MASTITIS 
5.2.1. Pathogenesis of acute clinical E. coli mastitis 
Pathogens causing intramammary infections have commonly been classified as environmental or 
contagious pathogens. E. coli is considered to belong to the group of environmental pathogens, 
because it originates from the organic matter in the environment of the cow (Nemeth 1994; Lipman 
et al., 1995; Hogan and Smith, 2003). Teat-end hyperkeratosis and a dirty udder significantly 
increase the risk of clinical E. coli mastitis (Breen et al., 2009). 
 
Knowledge of the pathogenesis of E. coli mastitis mainly originates from experimental studies. 
Even though the subject has been under research for several decades, it is not yet well understood. 
Development of the intramammary infection is fast and the clinical signs develop rapidly. The 
required infective dose of E. coli can be rather low; 30-50 cfu infused into the teat canal has 
consistently elicited severe clinical mastitis (Hill et al., 1978; Shuster et al., 1996; Kornalijnslijper 
et al., 2003). However, response to the challenge varies according to the inoculum dose, the strain 
used and the reaction of the individual cow. Bacterial numbers increase rapidly post challenge (PC) 
and often reach peak concentrations in milk within 10 h to 24 hours (Shuster et al., 1996; Rantala et 
al., 2002; Shpigel et al., 1997; Pyörälä et al., 1994; Hirvonen et al., 1999). Cow-to-cow differences 
in bacterial counts in milk have been reported to be up to 15-fold 3 h post-challenge and up to more 
than 800-fold 6 h later (Kornalijnslijper et al., 2004). During mild infections, E. coli is cleared from 
the infected quarter in 2 to 4 days, while in moderately affected cows it takes from 3 to 8 days 
(Kornalijnslijper et al., 2004; Hirvonen et al., 1999). Severity of clinical signs of mastitis has been 
significantly related to bacterial counts in the milk; a higher number of bacteria equates with more 
severe clinical signs (Lohuis et al., 1990; Vandeputte-Van Messom et al., 1993; Shuster et al., 1996; 
Hirvonen et al., 1999). 
 
The defense mechanisms of the cow usually eliminate the bacteria from the udder spontaneously 
(Hill et al., 1978). Adhesion of E. coli to mammary epithelium has not been considered to be 
essential for the development of intramammary infection, in contrast to Staphylococcus aureus 
infection (Opdebeeck et al., 1988; Anderson et al., 1977). However, recent studies of Döpfer et al. 
(2000 and 2001) showed that E. coli isolates from persistent intramammary infections were able to 
adhere to and invade cultured mammary epithelial cells. These E. coli strains invaded the cells less 
efficiently than S. aureus, but about as efficiently as Streptococcus dysgalactiae (Döpher et al., 
2001). 
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Polymorphonuclear (PMN) phagocytes, including neutrophils, basophils and eosinophils, play a key 
role in the containment of infection (Burvenich et al., 2007). PMN are the major effector cells of the 
bovine innate immune system and constitute a second line of defense after the mechanical 
protection afforded by the teat canal (Paape et al., 2003). A rapid neutrophil migration from blood 
to milk is followed by a subsequent decrease in bacterial counts in the mammary gland, as a result 
of phagocytosis and killing of bacteria (Hill et al., 1979; Shuster et al., 1996; Burvenich et al., 
2007). After experimental intramammary infusion of bacteria, it takes approximately 8 to 9 hours 
before PMN start to increase in the milk (Kornalijnslijper et al., 2004). Cows with moderate clinical 
signs have a more rapid PMN response in the infected gland compared with severe responders, 
which show a several hours of delay in leucocyte diapedesis into milk (Vandeputte-Van Messom et 
al., 1993). Hill et al. (1979) found that a slow diapedesis of neutrophils into the mammary gland is 
associated with the most severe cases of E. coli mastitis. This interval from ingress of the bacteria 
into  the  mammary  gland  before  PMN  influx  provides  time  for  bacteria  to  adapt  to  their  new  
environment in the mammary gland and to replicate there. A major determinant for the severity of 
experimental E. coli mastitis is bacterial growth in the acute phase before the massive influx of 
PMN (Kornalijnslijper et al., 2004). The bacterial load in milk after the first 6 hours of infection 
was reported to correlate significantly with the severity of the disease (Kornalijnslijper et al., 2004). 
 
In experimental E. coli mastitis, local signs of inflammation, such as swelling, warmth and firmness 
of the quarter, and changes in the appearance of the milk, usually start within 7 hours and reach 
their maxima in 10 to 14 hours (Vandeputte-Van Messom et al., 1993; Shuster et al., 1996). 
Systemic signs, which include rise in rectal temperature, decreased appetite, depression of rumen 
contractions, and impaired general attitude, appear together with local signs within 6 to 8 hours and 
peak about 9 to 12 hours PC (Lohuis et al., 1990; Pyörälä et al., 1994; Hirvonen et al., 1999; 
Vandeputte-Van Messom et al., 1993). Systemic signs disappear within 2 to 3 days post-inoculation 
(Lohuis et al., 1990; Pyörälä et al., 1994; Hirvonen et al., 1999) and local signs of the udder in one 
week (Hirvonen et al., 1999; Pyörälä et al., 1994). The signs of inflammation, as well as high milk 
SCC in the affected quarter, may persist for several weeks, or the quarter may become blind despite 
no growth of E. coli in the milk (Golodetz et al., 1983; Erskine et al., 1991; Pyörälä and Pyörälä, 
1997). 
 
Bacteremia was found significantly more often in cows with severe clinical signs (Wenz et al., 
2001b). Leucopenia in cows with acute coliform mastitis has been described in several studies. 
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Cows with more severe systemic signs have been found to have more profound leucopenia, but 
leucopenia is not considered to be a cause of bacteraemia (Wenz et al., 2001a).    
 
Severity of acute E. coli mastitis differs greatly among individual animals. Clinical signs of E. coli 
mastitis can differ from only mild changes in the appearance of the milk, without systemic signs, to 
severe clinical signs and strongly decreased milk production (Jones and Ward, 1990; Shpigel et al., 
1997; Pyörälä et al., 1994; Burvenich et al., 2007). The severity of E. coli mastitis depends on the 
age of the cow and on the lactation stage, i.e. older cows and cows in early lactation are more 
susceptible to infection (Hill et al., 1979; Hill 1981; Pyörälä and Pyörälä, 1998; Shuster et al., 1996; 
Mehrzad et al., 2002). In particular, the early lactating cows are more susceptible to fatal outcome 
from coliform mastitis, and only 30-50% of diseased cows return to full lactation (Jones and Ward, 
1990) regardless of antimicrobial and supportive therapy (Erskine et al., 1991). In early lactation the 
susceptibility of dairy cows to mastitis is increased, probably due to slow leukocyte recruitment to 
the mammary gland during the periparturient period and because of a negative energy balance and 
stress during early lactation (Suriyasathaporn et al., 2000). Experimentally induced endotoxin 
mastitis resulted in more severe response in early-lactating cows than in late-lactating cows; during 
early lactation the cows also had a decreased neutrophil function as compared with late-lactating 
cows (Lehtolainen et al., 2003c). A high number of coliform intramammary infections during the 
first 60 to 70 days of lactation can develop into severe mastitis and sepsis, defined as toxic mastitis 
(Smith et al., 1985a; Smith et al., 1985b; Hogan et al., 1989); when 25% of the cows either die or 
must be culled (Burvenich et al., 2007). Septic shock is a result of overproduction of inflammatory 
mediators after interactions of LPS with the host immune system. Coliform mastitis tends to be 
milder in middle and late lactation (Burvenich et al., 2007). Severity of mastitis is a result of 
interaction between immune defense of the host and bacterial characteristics. Burvenich et al. 
(2003) concluded in their review that cow factors rather than specific features of the bacterial strain 
mainly determine the severity of E. coli mastitis.  
.   
5.2.2. Intramammary persistence of E. coli 
Intramammary infections caused by E. coli are often of limited duration and bacteria are cleared 
from the quarter spontaneously. Recurrent episodes of clinical mastitis in the same quarter caused 
by E. coli have been considered to be exceptional (Lam et al., 1996). Persistent intramammary 
infections derived from the same E. coli genotype were reported from 5% to 24% among E. coli 
mastitis cases (Döpfer et al., 1999; Bradley and Green, 2001b). 
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Some authors have suggested that E. coli isolated from bovine mastitis would also have features 
similar to those of other animal and human pathogenic E. coli,  which  could  help  the  bacteria  to  
persist in the bovine mammary gland (Hill et al., 1979; Hogan et al., 1989; Lam et al., 1996; 
Bradley and Green, 2001b; Lehtolainen et al., 2003a; Blum et al., 2008). Lehtolainen et al. (2003a) 
reported that E. coli isolates positive for virulence factors S-fimbria, P-fimbria, CNF1 and CNF2 
were significantly associated with persistent mastitis. Mastitis-associated E. coli strains have been 
reported to adhere to and invade cultured mammary epithelial cells in vitro (Döpfer et al., 2000). E. 
coli strains isolated from persistent intramammary infection also survived and replicated inside 
cultured mammary epithelial cells (Dogan et al. 2006). 
 
5. 3. E. COLI MASTITIS THERAPY 
5.3.1. Antimicrobial therapy 
In E. coli intramammary infection, spontaneous elimination of bacteria is usually high (Hill et al., 
1979; Shuster et al., 1996; Burvenich et al., 2007). The use of antimicrobial agents in treatment of 
E. coli mastitis is contentious; in several studies no beneficial effects of antimicrobial treatment 
were demonstrated when compared with an untreated control group, although another studies 
reported some advantages of antimicrobial treatment (Table 1). 
 
The number of antimicrobials suitable for systemic treatment of coliform mastitis is limited and 
very few antimicrobial products have been approved specifically for this indication and even fewer 
have demonstrated favourable pharmacokinetic and pharmacodynamic properties (Constable et al., 
2008). Broad-spectrum antimicrobials, such as fluoroquinolones, cefquinome, ceftiofur and 
oxyteteracycline, have been used or recommended for the treatment of E. coli mastitis (Huxley 
2004; Shpigel et al., 1997; Cebra et al., 1996; Erskine et al., 2002; Morin et al., 1998; Wenz et al., 
2001b). These antimicrobials are considered to be critically important antimicrobials also in human 
medicine (Collignon et al., 2009). According to Ziv (1980), the ideal antibacterial for parenteral 
mastitis therapy would have a low MIC against the udder pathogen, have a high bioavailability from 
the intramuscular injection sites, be weakly basic or non-ionized in serum and sufficiently lipid 
soluble, have a low degree of protein binding and a long half-life in order to maintain activity in 
inflammatory secretions and not result in drug accumulation in specific organs. Few antimicrobials 
fulfil these requirements.  
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Table 1.  Studies on the efficacy of antimicrobial treatment of clinical E. coli mastitis with 
information on the type of study and whether significant benefits of the treatment were 
found. Routes of administration: intramammary (IMM) or systemic. 
 
Antimicrobial and 
route of 
administration 
Control used Type of 
study 
Result Reference 
Gentamicin systemic Erythromycin syst/ no 
antimicrobial syst 
Field study No benefits Jones & Ward 1990 
Gentamicin IMM No antimicrobial Experimental No benefits Erskine et al.1992 
Amoxicillin IMM, 
cephapirin IMM 
No antimicrobial Field data No benefits Guterbock et al.1993 
Trimethoprim-
sulfadiazine systemic 
Colistine sulfate IM Experimental No benefits Pyörälä et al. 1994 
Cefquinome IMM 
and/or systemic  
Ampicillin and 
cloxacillin IM 
Experimental Benefits Shpigel et al.1997 
Cephapirin IMM and/or 
oxytetracycline 
systemic and 
supportive treatment 
Supportive treatment 
only 
Field data Benefits Morin et al.1998 
Enrofloxacin systemic Procain penicillin, 
spiramycin, no 
antimicrobials 
Field data No benefits Pyörälä & Pyörälä 1998 
Enrofloxacin systemic No treatment Experimental Benefits Hoeben et al. 2000b 
Ceftiofur systemic No antimicrobial Field study * No benefits Erskine et al. 2002 
Enrofloxacin systemic No antimicrobial Experimental Benefits Rantala et al. 2002 
Enrofloxacin systemic Cefcinuinome IM Experimental 
and field data 
Benefits Poutrel & Dellac 2004 
Amoxicillin/cloxacillin 
IMM 
Penethamate 
hydroiodide syst 
Field data No benefits Sérieys et al.2005 
Danofloxacin systemic No treatment Experimental Benefits Poutrel et al. 2008 
*coliform mastitis 
 
 
 
According to the Finnish recommendations for the use of antimicrobials in treatment of severe E. 
coli mastitis in dairy cows, fluoroquinolones are the first choice and in high doses of trimethoprim-
sulfonamides the second-choice (Evira 2009). Enrofloxacin is a bactericidal, concentration-
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dependent fluoroquinolone antimicrobial authorized for treatment of dairy cattle in the EU. High 
concentrations of enrofloxacin, and particularly its active metabolite, ciprofloxacin, are achieved 
and maintained in the blood and milk of dairy cows (Kaartinen et al., 1995; Rantala et al., 2002). 
The pharmacokinetic properties of enrofloxacin are therefore favourable for the treatment of bovine 
mastitis. Milk does not significantly interfere with the antimicrobial activity of enrofloxacin in vitro 
(Fang and Pyörälä, 1996). Fluoroquinolones were also shown to have immunomodulatory capacity 
by increasing the killing ability of neutrophils, which may contribute to the therapeutic effect 
(Hoeben et al., 1997). Release of endotoxin from Gram-negative bacteria after a rapid kill by 
bactericidal antimicrobials is considered a risk in humans (Lepper et al., 2002), but has not been 
reported in the treatment of bovine E. coli mastitis (Pyörälä et al., 1994; Dosogne et al., 2002a).  
 
The activity of a trimethoprim-sulfonamide combination was reduced in milk (Fang and Pyörälä, 
1996), in which it is difficult to achieve and maintain therapeutic concentrations (Kaartinen et al., 
1999). Phagocytosis is impaired in the mammary gland and therefore antimicrobials with a 
bactericidal activity would be preferable for treatment of mastitis (Constable and Morin, 2003).  
 
Antimicrobials, to which coliforms either are or are not susceptible in vitro, have been reported to 
be equally efficacious in the treatment of E. coli mastitis in some field studies (Jones and Ward, 
1990; Pyörälä and Pyörälä, 1998). Results from treatment trials using antimicrobial agents have not 
been consistent, and most studies have failed to show beneficial effects (Table 1). Some advantages 
from antimicrobial treatment have reported from experimental studies, including faster elimination 
of bacteria, increased survival rate of the cows, and reduction in the loss of milk production 
(Table1). 
 
5.3.2. Non-antimicrobial therapy 
5.3.2.1. Anti-inflammatory therapy 
Non-steroidal anti-inflammatory drugs have been recommended for supportive treatment of 
coliform mastitis (Radostits et al., 2007) and are widely used by veterinarians in dairy practice 
(Katholm and Andersen, 1992; Green et al., 1997; Huxley et al., 2004). NSAIDs have been shown 
to be beneficial in revealing clinical signs, reducing fever and diminishing other effects of 
endotoxin in E. coli mastitis (Shpigel et al., 1994; Pyörälä and Syväjärvi, 1987; Rantala et al., 
2002).  
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Glucocorticoids are steroidal drugs used in treatment of severe mastitis (Erskine et al., 2003). They 
inhibit the production of inflammatory mediators, impair the transport of inflammatory cells to the 
inflammation site and decrease other inflammatory effects induced by LPS (Adams 2001). 
Dexamethasone-treated cows had a significantly lower rectal temperature, increased rumen motility, 
less udder inflammation and an improved 14-day milk yield compared with controls, when 
dexamethasone was given immediately after the LPS challenge (Lohuis et al., 1988b). 
Glucocorticoids have negative side-effects, as they suppress immune reaction, but if administered as 
a single dose during the early course of severe mastitis caused by coliform bacteria, the risk of 
adverse immune effects is considered small (Erskine et al., 2003).   
 
5.3.2.2. Lactoferrin 
Lactoferrin (Lf), an antibacterial substance in milk, acts as a bactericidal and LPS-neutralizing 
factor in the mammary gland (Appelmelk et al., 1994). Lf has been shown to be bacteriostatic for a 
variety of micro-organisms in vitro (Arnold et al., 1980; Rainard 1986; Lönnerdal and Iyer, 1995) as 
well as in vivo (Zagulski et al., 1986; Zagulski et al., 1989; Bhimani et al., 1999). The in vitro 
studies have shown inhibitory activity of Lf against E. coli (Rainard 1986; Kutila et al., 2003). This 
inhibitory activity is believed to result from the iron-chelating ability of Lf, making iron unavailable 
to bacteria (Weinberg 1978), but Lf molecules were also reported to be directly toxic to microbes 
and neutralize the effects of LPS (Appelmelk et al., 1994).  
 
Lactoferrin combined with antibiotics was tested for treatment of bovine mastitis caused by S. 
aureus with some beneficial effects (Komine et al., 2006; Lacasse et al., 2008). Lf increased 
survival rates in an experimental E. coli model with mice and rabbits (Zagulski et al., 1986; Rainard 
1986). Lf concentration in milk from cows with peracute E. coli mastitis was shown to be initially 
lower than that in cows with less severe mastitis and thus perhaps insufficient to inhibit bacterial 
growth (Harmon et al., 1975; Kawai et al., 1999). In theory, Lf could be beneficial in the treatment 
of E. coli mastitis as a non-antibiotic antibacterial and endotoxin-neutralizing alternative. 
Disposition kinetics of Lf after intramammary administration were reported by Kutila et al. (2002).  
 
5.3.2.3. Frequent-milking 
Frequent milking, a traditional treatment for severe mastitis, has been commonly recommended as a 
supportive treatment of severe mastitis in Finland. It has been recommended for use in conjunction 
with oxytocin to stimulate milk let-out (Radostitis et al., 2007). In theory, its efficacy is based on 
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removing harmful toxins and bacteria from the udder and thereby decreasing pain and 
inflammation. On the other hand, in removing milk, humoral anti-inflammatory agents and 
bactericidal proteins such as lactoferrin are also removed.  In one congress report the efficacy of 
frequent milking was found to be better than systemic antimicrobial therapy for the treatment of 
severe experimental E. coli mastitis, but the number of the cows treated was small (Stämpfli et al., 
1994). Frequent milking showed no beneficial effects in an experimental study with an E. coli 
mastitis model (Leininger et al., 2003). 
 
5.3.2.4. Other approaches 
Some new non-antimicrobial therapeutic approaches, such as recombinant bovine soluble CD14, 
the cellular receptor for LPS in macrophages and neutrophils, have been investigated in pilot 
experiments. CD14 was shown to reduce severity of E. coli mastitis in a bovine experimental model 
(Lee et al., 2003).  
 
5.4. PREVENTION OF E. COLI MASTITIS 
5.4.1. Management aspects 
The two main preventive measures of intramammary infection are to minimize the challenge from 
the contaminated environment and to maximize the cow’s own defense (Bradley and Green, 2004). 
Common sources of exposure to Gram-negative bacteria include manure, contaminated bedding, 
water, soil and feedstuffs. The management practices that reduce the number of bacteria in the 
environment of the cow generally decrease clinical mastitis caused by Gram-negative bacteria 
(Hogan and Smith, 2003). A dirty udder and injured teat skin significantly increase the risk of 
clinical E. coli mastitis (Breen et al., 2009). Post-milking dipping of the teats with antiseptic agents 
has proven to be unsuccessful in the control of coliform mastitis (Pankey et al., 1984), as has also 
dry cow therapy in general (Radostits et al., 2007). However, dry cow therapy with an antimicrobial 
compound efficacious against Gram-negative bacteria decreased episodes of new clinical mastitis 
caused by Gram-negative bacteria post partum (Bradley and Green, 2001a). Inadequate nutrition, 
stress and pregnancy can have a dramatic negative impact on the immune system of the cow 
(Lippolis 2008). A clean, dry, cool and comfortable environment, proper feeding and adequate 
supplementation of the diet with vitamins and trace elements are important for maintaining good 
udder health (Bradley and Green, 2004; Lippolis 2008; Pyörälä 2008). 
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5.4.2. Vaccination 
Prophylactic immunization is used in some countries to prevent coliform mastitis. Vaccines 
developed using the common core antigen of coliform bacteria, administered systemically at 
drying-off and again 3 weeks before the calving date, have been in use in North America for many 
years (Hogan et al., 1992; Wilson and González, 2003; Wilson et al., 2007a). The common core 
antigen was recently authorized in the European Union in a combination mastitis vaccine (EMA 
2009). The duration of immune response induced by vaccine was relatively short (Wilson et al., 
2007a; Wilson et al., 2007b). Vaccination is able to reduce the severity of clinical signs and protect 
cows from culling or death and to reduce the milk loss. However, the incidence of clinical mastitis 
has not been reduced (Wilson et al., 2007a; Wilson et al., 2007b). In some earlier studies, a reduced 
risk for clinical mastitis in vaccinated cows was reported (Cullor 1991; Hogan et al., 1992). In 
addition to the common core antigen, iron regulated outer-membrane protein vaccines against 
coliform mastitis have also been investigated (Lin et al., 1999).  
 
5.4.3. Genetic engineering 
Genetic engineering is one tool suggested to increase host defense against mastitis (Bramley et al., 
2001; Pyörälä 2002; Maga et al., 2005). Increasing mastitis resistance by improving the immune 
response through modifying activity of genes or incorporating beneficial genes from other 
organisms, has been proposed to have a positive impact on cow welfare and economics of milk 
production (Oliver 2005). The transgenic approach to enhance mastitis resistance was studied in a 
mouse model (Kerr et al., 2001). In the first published cow model (Wall et al., 2005), cows carrying 
a gene coding for an anti-staphylococcal peptide, lysostaphin, were shown to resist S. aureus 
intramammary infection. The first transgenic cows with the hLf gene were reported to express Lf in 
their milk at a concentration of 0.3 to 2.8 mg/ml (Brink et al., 2000; Van Berkel et al., 2002). A 
gene encoding human lactoferrin (hLf) in the bovine mammary gland could be a good candidate to 
increase resistance of dairy cows to coliform mastitis by transgenesis,  
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6. AIMS OF THE STUDY  
 
The general aim of this thesis was to investigate the host response, characteristics of bacteria, and 
the efficacy of antimicrobial and non-antimicrobial treatments of bovine E. coli mastitis.  The  
specific aims were: 
 
1. To investigate host response in two consecutive intramammary challenges with Escherichia coli 
and to evaluate the possible carry-over effect when the same animals were used in an experimental 
model.                                                                                                
 
2. To compare the efficacy of the combination of systemic enrofloxacin and supportive treatment 
with supportive treatment only in dairy cows with clinical E. coli mastitis under field conditions.   
 
3. To identify possible specific virulence genes and phylogeny types of E. coli associated with 
severity of clinical mastitis and persistence of the intramammary infection. 
 
4. To investigate the efficacy of bovine lactoferrin as an alternative to antimicrobials in the 
treatment of E. coli mastitis. 
 
5. To investigate the prophylactic effect of expression of human lactoferrin in the milk against E. 
coli mastitis. 
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7. MATERIALS AND METHODS 
 
7.1. Animals 
 
Seven primiparous dairy cows (three Ayrshire and four Friesian-Holstein), calved on average 3 
months earlier, were used in the experimental study on the effect of two consecutive E. coli 
challenge on acute phase response (study I). Six primiparous, early-lactating dairy cows (five 
Ayrshire and one Finnish Landrace) were used in the study on the efficacy of lactoferrin in the 
treatment of E. coli mastitis (study IV). 
 
In the study on the effect of recombinant human lactoferrin (rhLf) on experimental E. coli mastitis 
(study V) seven primiparous, early-lactating Friesian-Holstein transgenic cows (produced and 
owned by Pharming Group NV, The Netherlands) expressing human lactoferrin (hLf) in their milk 
were used. The control group consisted of six non-transgenic normal, early lactating Friesian-
Holstein dairy cows. The cows were confirmed as being transgenic using a calf by hLf calf PCR 
analysis (Brink et al., 2000). The mean concentration of rhLf in the milk of these cows was 2.9 
mg/ml (Hyvönen et al., 2006). 
 
Milk somatic cell count (SCC) was < 100 000 cells/ml in all quarters of the experimental cows in 
studies  I,  IV and  V prior  to  the  experiments.  The  cows were  clinically  healthy  and  there  was  no  
bacterial growth in their milk samples collected before the experiments. 
 
Lactating dairy cows with acute clinical mastitis (IDF 1999), which the veterinarian suspected to be 
caused by coliform bacteria in the practice areas of the Ambulatory Clinic of the University of 
Helsinki and the Lammi Veterinary Practice during 2003-2006, were included in the field trial 
(study  II).  The  final  decision  to  include  a  cow in  the  trial  was  made  on  the  basis  of  the  result  of  
bacteriological  examination  of  the  pre-treatment  milk  sample.  A total  of  132  cows from 61  herds  
were finally enrolled in the study. Days in milk (DIM) and number of parities (1, 2 and ≥ 3) were 
recorded on the study form.  
 
The Ethics Committees of the University of Kuopio and the University of Helsinki approved the 
experimental study protocols and The Board for Gene Technology in Finland the use of transgenic 
animals. 
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7.2. Study designs in experimental studies (study I, IV and V) and 
field trial (study II)  
 
The same procedure for bacteria inoculation was used in the studies I, IV and V. One udder quarter 
of each cow was inoculated via the teat canal with a dose of E. coli of approximately 1500-1700 cfu 
(from 1400 to 2300 cfu), which was suspended in 10 ml of pyrogen-free saline. 
 
The effect of two consecutive E. coli challenges on the acute phase response of the cow (study I) 
was studied by repeating the challenge after 14 days in another udder quarter of the same cow. 
Cows in study I were treated with a dose of flunixin meglumine at 2.2 mg/kg once at 12 hours PC 
(Finadyneâ, Schering-Plough, Farum, Denmark). 
 
In the experiment on the efficacy of lactoferrin in the treatment of E. coli mastitis (study IV) the 
cows were randomly allocated to two treatment groups. Treatment was started 12 hours PC. Three 
of the cows received 1.5 g of Lf via the intramammary route three times after milking at 12, 20 and 
36 hours PC. The remaining three cows received, as a positive control treatment, enrofloxacin 
(Baytrilâ, Bayer AG, Leverkusen, Germany) at 5 mg/kg first i.v. 12 hours PC, then s.c. twice 24 
hours apart (at 36 and 60 hours PC). Flunixin meglumine (Finadyneâ, Schering-Plough, Farum, 
Denmark 2.2 mg/kg i.v.) was administered to all cows 12 hours PC, and a second dose 36 hours PC. 
A crossover design was used in study IV, so that each cow served as its own control: three weeks 
after the first challenge, a contralateral udder quarter of the same cow was inoculated. 
 
In the field trial (study II) the cows were randomly allocated to two treatment groups, enrofloxacin 
and non-enrofloxacin (non-treated), using cow ID number (even and odd numbers). Cows were 
treated systemically with enrofloxacin (Baytrilâ, Bayer HealthCare AG, Germany) in the 
enrofloxacin group. The dosage used was 5 mg/kg administered twice at an interval of 24 h; the first 
dose was given intravenously by the veterinarian and the second dose subcutaneously by the herd 
owner. Cows in both groups received the non-steroidal anti-inflammatory drug ketoprofen either 
intravenously or intramuscularly at 3 mg/kg (Comforionâ, Orion Oyj, Finland) or 4 mg/kg per os 
(Dolovet®, Vetcare Oy, Finland) daily for 1-3 days. Because the clinical diagnosis of E. coli 
mastitis was not accurate for the initial farm visit, experimental treatment was combined with 
penicillin G intramammaries (Carepenâ 600 mg, Vetcare Oy, Finland), once a day into the affected 
 28
quarter, until confirmation of the diagnosis. Use of frequent milking of the affected quarter was to 
the responsibility of the owner. Fluid therapy was used by the veterinarian when considered 
necessary on the basis of clinical signs. All treatments were recorded by the veterinarian on the 
study data collection form. 
 
7.3. Clinical observations  
 
Systemic and local signs of the cows were monitored throughout the experiments in studies I, IV 
and V; during the first two days every 4 hours and thereafter twice daily, when the cows were 
milked. Heart rate, rectal temperature, rumen motility, appetite and general attitude were recorded. 
The udder was palpated for soreness, swelling and hardness, and quarter milk samples were 
evaluated visually for clotting, colour changes and consistency each time the cows were milked 
(Pyörälä et al., 1994). The local and systemic signs were scored on a three-point scale (1 = no signs 
to 3 = severe signs) (Pyörälä et al., 1994). Daily milk yield was measured throughout the study. 
 
Each cow was examined clinically by the attending veterinarian in the field trial (study II) at the 
time of enrolment (day 0). Clinical signs (local signs, such as swelling and pain in the udder and 
milk appearance, and systemic signs such as rectal temperature, general attitude and appetite) and 
CMT scores using the Scandinavian scoring system from 1 to 5 (Klastrup and Schmidt Madsen, 
1974) were recorded on the data collection form by the veterinarian. Clinical signs were scored 
according to a 3-point scale (1 = no signs to 3 = severe signs), as described earlier (Pyörälä et al., 
1994). On day 2 and at 3-4 weeks (defined as day 21) post-treatment, the farmer estimated milk 
production (normal, diminished, or a blind quarter) and clinical recovery (visible or palpable signs) 
of the affected quarter, carried out a CMT and recorded the results on the data collection form. 
Frequent milking (emptying of the infected quarter at least twice a day in addition to the regular two 
milkings per day) at the acute stage was also recorded. 
 
During the field trial assessments were made of clinical and bacteriological cures on day 2 and on 
day 21 and return to milk production of the affected quarter on day 21 compared to quarter milk 
production prior to mastitis (returned, diminished, blind quarter). A cow was defined as clinically 
cured if no systemic signs were present, the affected quarter was free from any clinical signs, the 
milk appearance was normal and milk was acceptable for delivery. Growth of E. coli in the follow-
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up milk samples on days 2 and 21 was used to assess the bacteriological cure. If bacteria other than 
E. coli were isolated in the follow-up sample on day 21, the quarter was defined as reinfected. 
 
A cow was classified as “survived” if it remained in the herd (not dead, euthanized or culled 
because of E. coli mastitis) during the three-week post-treatment period. To evaluate the long-term 
presence of the cow in the herd, the farmer was asked six months later if the cow was still in the 
herd, after which the cow was classified as “remaining” or “not remaining”. 
 
7.4. Bacterial strain used in experimentally induced mastitis 
 
The E. coli strain FT238 (isolated from clinical mastitis) was used to induce experimental mastitis 
in  studies  I,  IV  and  V.  The  strain  was  non-hemolytic,  intermediately  serum-resistant,  and  
susceptible to enrofloxacin in vitro with a minimum inhibitory concentration (MIC) < 0.25 μg/ml 
(Pyörälä et al., 1994; Rantala et al., 2002). The strain was also susceptible to bovine lactoferrin 
(bLf) in vitro with a complete inhibition of the growth at a concentration of > 1.67 mg/ml (Kutila et 
al., 2003) as well as for hLf at a concentration of ≥ 1.5 mg/ml.   
 
The E. coli strain was cultured and grown on blood agar plates overnight. A few colonies were 
subcultured in Iso-Sensitest Broth (ISB broth, Oxoid, Basingstoke, Hampshire, England) and 
incubated for 18 hours at 37°C. The broth culture was centrifuged, and the pellet was resuspended 
in sterile saline and diluted to an estimated concentration of 108 cfu/ml. The final concentration of 
the bacterial inoculate used in challenges was determined by culturing and colony count.  
 
7.5. Milk and blood samples 
7.5.1. Sampling 
In study I, aseptic milk samples were collected from the experimental and contralateral quarter 
before the challenge and 12, 20, 36, 44, 60, 68, 84,108, 132 and 156 hours PC for bacteriological 
assessment and determination of SCC, N-acetyl-β-D-glucosaminidase (NAGase) activity, and 
concentration of serum amyloid A (SAA), haptoglobin (Hp) and lipopolysaccharide binding protein 
(LBP) in the milk. Blood samples were collected before challenge and 12, 16, 20, 24, 36, 44, 60, 68 
and 156 hours PC. Serum was separated and kept frozen at -70°C for later determination of 
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concentrations of SAA, Hp and LBP. EDTA blood was collected for leukocyte count (WBC) and 
packed cell volume (PCV) determination. 
 
In the study IV milk samples were taken aseptically from the challenged and the contralateral 
quarters were collected at 120 and 12 hours before the challenge and at 12, 16, 20, 36, 40, 44, 60, 
84, 108, 132 and 156 hours and at 1, 2 and 3 weeks PC for bacteriological assessment, SCC, and 
milk  NAGase  activity  determinations.  Blood  samples  were  collected  at  12  hours  before  the  
challenge and then at 12, 16, 20, 36, 60, 84 and 180 hours PC and kept frozen at -70° C for later 
use. 
 
In study V aseptic milk samples from the challenged and contralateral quarters were collected 12 
hours before the challenge, immediately before the challenge, and every four hours PC during the 
first 24 hours. Milk samples were taken before milking at 36, 44, 60, 84, 132, 156, 180 hours and 
finally 14 days after the challenge. Concentrations of hLf and bLf, bacterial count, SCC, NAGase 
activity  and  concentrations  of  SAA,  Hp  and  TNF-α were determined from the milk samples. 
Concentrations of LPS were determined from the milk samples taken 12 hours PC. Blood samples 
were collected at 12 hours and immediately before the challenge, and every four hours PC during 
the first 24 hours and then at 36, 60, 84, 168 hours (7 days) and 14 days. Serum was separated and 
kept frozen at –70º C for determination of concentrations of TNF-α, SAA, Hp, cortisol, urea, 
creatinine, albumin, total protein, alanine aminotransferase (ALAT) and alanine aminofosfatase 
(AFOS). EDTA blood was collected for WBC and PCV. 
 
In the field study (study II), a 4 ml milk sample was collected aseptically from the affected quarter 
before treatment (day 0) and 2 days (day 2) and 3-4 weeks (day 21) post-treatment by the 
veterinarian or a trained owner. Follow-up milk samples taken on days 2 and 21 were stored frozen 
and cultured within a month. 
 
7.5.2. Analytical methods for the milk and blood samples 
SCC was measured with a Fossomatic instrument (Foss Electric, Hillerod, Denmark) in the 
laboratory  of  Valio  Oy  (Lapinlahti,  Finland).  SCC  values  over  30x106 cells/ml were recorded as 
30x106 cells/ml in study I and over 20x106 cells/ml were recorded as 20x106 cells/ml in study V.    
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In study IV the concentration of LPS in the milk samples at 20 hours PC and in study V at 12 hours 
PC was determined using Limulus Amaebocyte Lysate (LAL) test (BioWhittaker, Walkersville, 
MD,  USA) at  the  Regional  Institute  of  Occupational  Health  of  Kuopio,  Finland.  The  ratio  of  the  
concentration of LPS to the bacterial count was calculated for both treatment groups in study IV.  
 
Milk NAGase activity, an indicator of the degree of inflammation and tissue damage of the affected 
quarter, was measured using the fluorogenic method of Kitchen and co-workers (1978) with a 
microplate modification developed by Mattila and Sandholm (1985). In studies I, IV and V milk 
NAGase activity values higher than 2.8 pmol 4-MU/min/µl were recorded as 2.8 pmol 4-
MU/min/µl and after adopting the revised procedure in analysis in study II, values higher than 24.49 
pmol 4-MU/min/µl were recorded as 24.49 pmol 4-MU/min/µl, the upper limit for quantification. 
 
The concentrations of SAA in milk and serum were determined using a commercial ELISA test 
(Tridelta Development, Wicklow, Ireland). Milk and serum samples were initially diluted 1:500 and 
1:50. For very high SAA values, samples were diluted as necessary up to 1:15000 (maximum 
concentrations 2250 μg/ml).  
 
Milk and serum Hp concentrations were determined using the method based on the ability of Hp to 
bind to hemoglobin (Makimura et al., 1982) and using tetramethylbenzidine as the substrate 
(Alsemgeest et al., 1994). The assay is aimed at determining of Hp in serum, but was adapted to be 
used for milk (Hyvönen et al., 2006). Lyophilized bovine acute phase serum was used as a standard 
and calibration was according to the European Union concerted action on standardization of animal 
acute phase protein (APP) (number QLK5-CT-1999-0153).  
 
LBP concentrations in serum and milk were determined with a commercially available LBP ELISA 
kit, cross-reacting with bovine LBP (LBP ELISA for various species, Hycult Biotechnology, Uden, 
The Netherlands). Milk and serum samples were initially diluted 1:500 and 1:1000 respectively, and 
assayed following the instructions of the manufacturer. For high concentrations, milk was diluted 
up to 1:5000 and serum up to 1:2000. The LBP concentration was determined by extrapolation 
using linear regression from a standard curve of known human LBP concentrations. 
 
In study V an ELISA for the quantification of bovine TNF-α in plasma (Carstensen et al., 2005) was 
modified for serum as described in Lehtolainen et al. (2004). The detection limit of the ELISA was 
0.5 ng/ml for the serum. The milk samples were centrifuged and the clear supernatants were used 
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for the ELISA analysis of bovine TNF-α (study V). The detection limit of the ELISA was 1.0 ng/ml 
for the milk. 
 
Serum  cortisol  (study  V)  was  analyzed  using  a  radioimmunoassay  (Coat-A-Count  Cortisol,  
Diagnostic Product Corporation, Helsinki, Finland). The results were expressed as nmol/l. 
 
Hematological parameters (WBC and PCV) in study I, IV, and V,  were determined within 24 hours 
after sampling using an automated multiparameter analyzer with software for animal samples (Cell-
Dyn  3700  System,  Abbott  Diagnostic  Division,  Abbott  Park,  IL,  USA).  In  study  IV  serum  urea,  
creatinine, albumin and total protein were measured using enzymatic kinetic methods with an 
automatic  analyzer  (Kone  Pro,  ThermoClinical  Labsystems,  Espoo,  Finland).  For  ASAT  and  
AFOS, activities were measured using an automatic analyzer (Kone Specific, ThermoClinical 
Labsystems, Espoo, Finland).  
 
7.6. Preparation and analyses of lactoferrin (study IV and V) 
 
Bovine Lf used in study IV was purified from cheese whey, or concentrated cheese whey, using an 
expanded bed absorption chromatography method developed by Isomäki (1999). The native form of 
Lf was used with an iron content of approximately 8-15%. The LPS contamination in Lf was tested 
with the Limulus amoebocyte lycate (LAL) test using the kinetic BioWhittaker-QCL method 
(Walkersville, MD, USA). The LPS content of Lf did not exceed 1.7 ng/ml.  
 
Quantitative recombinant hLf and natural bLf analyses in milk were conducted using enzyme-
linked immunosorbent assays (ELISAs) in study V. hLf was measured by rhLf-specific ELISA 
according to the procedure recommended by Pharming, and anti-hLf was absorbed with Sepharose 
to remove cross-reacting antibodies (van Berkel et al., 1996). bLf levels were measured using a 
bovine  Lf  ELISA  quantification  kit  (Bethyl  Laboratories,  Inc.  Montgomery,  USA).  The  cross-
reactivity of bLf with hLf was tested with bLf and hLf standards (Sigma, St. Louis, USA). The level 
of detection was 0.008 mg/ml. 
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7.7. Bacteriological methods  
 
Bacterial counts in the milk samples in experimental studies (study I, IV and V) were determined by 
preparation of 10-fold dilution series of milk in sterile saline. Bacteria were cultured on blood agar 
at 37º C for 24 hours using serial dilutions and counted using a routine plate count method. 
 
In the field trial (study II) a sample of 0.01 ml of milk was cultured on blood agar (6-10% sheep 
blood) (Tammertutka, Tampere, Finland). Isolates were identified as E. coli by colony morphology, 
Gram-stain and typical growth on eosin methylene blue (EMB) agar (Hogan et al., 1999). The 
diagnosis was confirmed by the API 20E test (bioMérieux, Marcy l´Etoile, France) at the Finnish 
Food Safety Authority Evira (Helsinki, Finland).  Follow-up milk samples taken on days 2 and 21 
were stored frozen and cultured within a month.  
 
E. coli isolates from pre- and post-treatment samples at 3 weeks served as the material in study III. 
A total of 144 isolates originated from the pre-treatment samples and 10 from the follow-up 
samples 3 weeks post-treatment. Antimicrobial susceptibility of the initial E. coli isolates (study II 
and III) was tested using the VetMICTM microdilution method (SVA Uppsala, Sweden) (CLSI 
2004) using the epidemiological cutt-offs of EUCAST (2008), except for ciprofloxacin, for which a 
cut-off > 0.06 μg/ml was used. Susceptibilities to ampicillin, streptomycin, tetracycline, 
sulfametoxazol, trimethoprim, kanamycin, kephotaxim, nalidixin acid, ciprofloxacin, gentamicin, 
florfenicol and ceftiofur were investigated. Isolates of E. coli from pre- and post-treatment samples 
were genotyped using pulsed-field gel electrophoresis (PFGE) at the Finnish Food Safety Authority 
Evira (Kuopio, Finland). DNA was extracted, digested with Xbal and subjected to PFGE essentially 
according to the CDC/PulseNet protocol for E. coli O157:H7 (CDC 2008). Salmonella Braenderup 
strain H9812 DNA digested with Xbal was used as a DNA size standard. The PFGE patterns were 
analyzed for similarity by visual comparison. Strains were considered distinct if the pulsotypes were 
not identical. 
 
The  polymerase  chain  reaction  (PCR)  was  used  to  analyze  the  genes  of  colisin  V  plasmid  (cva), 
vacuolating autotransporter protein (vat), temperature-sensitive hemagglutinin (tsh), aerobactin 
(iucD), P-fimbria (papC),  yersinia  bactin  (irp2), increased serum survival (iss) and 
enteroaggregative heat-stable toxin (astA) from the isolates (Ewers et al., 2005). PCR described by 
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Paton and Paton (2002) was used to detect genes of shigatoxin 1 and 2 (stx1 and stx2), intimin 
(eaeA),  enterohemolysin  (ehxA) and autoagglutinating adhesin (saa) and that by van Bost et al. 
(2003) to detect S-fimbria (sfaD), F17 fimbria (f17A) and afimbrial adhesin AFA8 (afa8E). The 
gene for cytotoxic necrotizing factor 2 (cnf2)  was  analyzed  as  described  earlier  (Kaipainen  et  al.,  
2002). Isolates were assigned to a phylogeny group using the PCR method of Clermont et al. 
(2000).  
 
7.8. Statistical analyses 
 
Linear random-intercept models were used in study I to explore time trend differences between 
challenge times in milk production data, milk SCC, milk NAGase, WBC and all APP 
measurements. Bacterial counts in milk and local and systemic sign differences between challenges 
were tested using generalized linear mixed models in which a Poisson distribution was used for 
response  variables.  The  cow  was  included  as  a  random  factor.  Overall  time  trend  differences  
between challenges were tested with an F-test. Due to different intervals between sampling, 
isotropic spatial exponential correlation structures were used for modeling serial correlations of 
repeated measurements within cows. Logarithmic transformation of milk SCC, milk NAGase and 
APPs in milk and serum was used. The nlme-package (Pinheiro et al. 2006) with statistical software 
R 2.5.0 (R Development Core Team 2006) was used for fitting linear random-intercept models and 
generalized linear mixed models were fitted using the GLIMMIX procedure (2006) software with 
the SAS/STAT 9.1 (SAS Institute Inc., Cary, NC, USA). 
 
In  study  II,  statistical  analyses  were  carried  out  using  Stata  Intercooler  version  9.0  (Stata  
Corporation,  Texas,  USA).  The  unit  for  the  analysis  used  was  the  cow.  Logistic  and  linear  
regression models were used as described below. The clustering effect of a herd was estimated with 
logistic and linear mixed models. Continuous variables (DIM and milk NAGase activities) were 
examined for linearity with the outcomes. To improve linearity, NAGase activity on day 0 and 21 
was logarithmically (natural logarithmic) transformed; NAGase activity on day 2 was bimodally 
distributed and therefore, for the purposes of the analysis the activity at this time analyzed 
dichotomously. Dichotomous variables were clinical signs (mild/severe), enrofloxacin treatment 
(yes/no), amount of bacterial growth on day 0 (< 10 cfu/μl / ≥ 10 cfu/μl), fluid therapy given 
(yes/no), use of frequent milking (yes/no) and reinfection on day 21 (yes/no). Parity was used as a 
categorical variable (parities 1, 2 and ≥ 3). The variables were subjected first to univariable and then 
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multivariable analyses. Variables with a P-value of less than 0.25 in a univariable analysis were 
entered into the multivariable analysis. Collinearity was tested with a pair-wise correlation test. 
Enrofloxacin treatment was always kept in the final model. Possible confounding factors (DIM, 
frequent milking, fluid therapy and parity) were tested separately with all models and were kept in 
the analysis if they affected the results. No significant correlations or interactions were found 
among any of the variables studied. A multivariable logistic regression model was used for the 
outcomes other than NAGase activity. For outcome of NAGase activity on day 21, a multiple linear 
regression model was used. Full and nested models were compared with a likelihood ratio test. A 
simple logistic regression model was used to test the effect of survival of a cow, because of the 
small  number  of  dead  or  killed  cows on  day  21.  Model  fit  was  assessed  with  the  assumptions  of  
normality and homogeneity of variances, which were evaluated by checking the residuals. The two-
way sample size calculation for the statistical analyses in final models allowed detection of 
differences of ≥ 25% between treatment groups for all  outcomes evaluated; the power of analyses 
was 0.80.  
 
Three logistic regression models were used in study III. Parity (1, 2, ≥ 3 times), phylogeny groups 
(A, B1, B2, D) and DIM (1 week ante partum to 3 weeks post partum, > 3 weeks to 120 days pp, > 
120 days pp) were measured on a nominal scale and used as categorical variables. Dichotomous 
variables were virulence genes, phylogeny groups and antimicrobial susceptibilities, and 
additionally the following variables: clinical signs on day 0, NAGase activity on day 0 and 
antimicrobial treatment. Each of the virulence genes and antimicrobial resistance traits were 
included in the statistical models only if data consisted of at least 10 positive findings. 
Multivariable logistic regression models were used for the outcomes (clinical signs on day 0, milk 
NAGase activity on day 0, bacterial persistence on day 21). The clustering effect of a herd was 
estimated with a logistic mixed model. The herd was included as a random effect with models of 
clinical signs on day 0 and bacterial persistence. The variables were subjected first to univariate, 
then multivariable analyses. Variables with a P-value of less than 0.15 in a univariate analysis were 
retained in the multivariable analysis after testing the variables for correlation with pair-wise 
correlation test. Possible confounding factors were kept in the analysis when there was a likely 
effect  on  the  results.  Significant  correlations  (>  0.65)  and  interactions  were  taken  account  of  in  a  
final model as the most significant variable was chosen to representative of the group. In the logistic 
regression model of milk NAGase activity on day 0, full and nested models were compared with a 
likelihood ratio test. Model fit was assessed with the assumptions of normality and homogeneity of 
variances, which were evaluated by checking the residuals. 
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In study IV, repeated measures analysis of variance with treatment and sampling time as within-
factors was used to test for differences for variables (SCC, NAGase activity, bacterial counts, 
systemic and local clinical signs, and total and quarter milk yields) between the two treatments. The 
significance of effects was evaluated by using Greenhouse-Geisser adjusted P-values. Possible 
carry-over effects were assessed using t-test procedures (Jones and Kenward 1989). Statistical 
significance of the ratio of LPS to bacterial count was determined using a Wilcoxon Signed Ranks 
Test. 
 
In study V, the effects of time post-challenge on concentrations of measured parameters and on 
clinical signs were analyzed statistically using mixed-model analysis of variance (SPSS 11.0, SPSS 
Inc., Chicago, IL, USA). 
 
For all tests, P < 0.05 was considered significant. 
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8. RESULTS 
 
8.1. The effect of two consecutive experimental E. coli challenges 
(study I)  
 
After both challenges all cows became infected and developed clinical mastitis within 12 hours of 
inoculation. All cows showed systemic and local inflammatory response after challenges. Systemic 
response began within 12 hours and was moderate in all cows. Systemic signs disappeared in cows 
after both challenges by 36 hours PC. Local signs were detected at the end of the experimental 
period of 6 days PC after the first challenge, but disappeared by 2.5 days PC after the second 
challenge. In both challenges cows developed a similar systemic response, but their local responses 
varied  more.  After  the  second challenge,  local  signs  were  significantly  milder  (P  <  0.05),  but  no  
statistically significant differences were noted in systemic signs (Figure 1).  
 
Figure 1. Mean scores for systemic and local signs in two consecutive E. coli challenges at 
an interval of 2 weeks. Values are mean scores for six cows with standard error of the 
mean (SEM) represented by vertical bars. 
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The total daily milk yield during the course of the experiment was significantly higher after the 
second challenge (Figure 2). Bacterial counts in the milk of the challenged quarters peaked 12 hours 
PC at both challenge times. Bacteria were still isolated in low numbers from one cow (80 cfu/ml) 6 
days PC after the first challenge, but after the second challenge they were totally eliminated in all 
cows within 68 hours. Overall bacterial counts were lower at the second challenge (Figure 3). 
 
 
Figure 2. Mean total daily milk yield and milk yield of the experimentally infected quarter 
in two consecutive E. coli challenges at an interval of 2 weeks. The values are means for 
six cows with SEM represented by vertical bars. 
 
 
 
 39
 
Figure 3. Mean somatic cell counts and bacterial counts in milk in two consecutive E. coli 
challenges at an interval of 2 weeks. Values are means for six cows with SEM represented 
by vertical bars. 
 
After the first challenge, milk NAGase activity remained elevated over the experimental period of 6 
days, but returned to the baseline value within 6 days after the second challenge. After the second 
challenge, milk SAA and Hp concentrations decreased significantly faster (Figure 4). LBP was still 
increased 6 days after the first challenge, but had reached the pre-challenge level by that time after 
the second challenge (Figure 4). 
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Figure 4. Concentrations of SAA, LBP, Hp and NAGase activity in milk in two consecutive 
E. coli challenges at an interval of 2 weeks. Values are means for six cows with SEM 
represented by vertical bars. 
 
 
The concentrations of SAA and Hp in serum were lower in the second challenge, but the difference 
was only statistically significant for Hp (Figure 5). Serum LBP increased rapidly after the first and 
second challenge; again concentrations were lower after the second challenge. Leucopenia was 
noted at both challenges (Figure 5). Leucocyte counts were higher after the second challenge and 
the difference was statistically significant (Figure 5).  
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Figure 5. Concentrations of SAA, LBP and Hp in serum and blood leucocyte counts in two 
consecutive E. coli challenges at an interval of 2 weeks. Values are means for six cows 
with SEM represented by vertical bars. 
 
8.2. The efficacy of enrofloxacin in the treatment of E. coli mastitis 
(study II)   
 
A total of 132 cows (mean 2.2 cows per herd) with confirmed growth of E. coli in the pre-treatment 
milk sample were included in the study (Table 2). Fewer E. coli bacteria than 10 cfu/μl milk were 
isolated in 8.4% of the pre-treatment samples. The enrofloxacin-treated group comprised 64 cows 
(48.5%) and the non-treated group 68 (51.5%) cows. According to clinical signs on day 0, 80.1% (n 
= 105) of the cows had moderate to severe signs (severity score ≥ 2) and 19.9% (n = 26) mild signs 
(score ≤ 1.5). All cows receiving fluid therapy (n = 40), had moderate to severe disease.  
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Table 2. Descriptive statistics and univariable results of naturally occurring acute E. coli 
mastitis1.  
 
Dichotomous variables Level 
Frequency 
(%) g 
Enrofloxacin 
treated (%) 
Non-
treated (%) 
Bacteriological cure 
 on d 2 e,f Not-cured 72 (72.0) 31 (64.6) 41 (78.8) 
 Cured 28 (28.0) 17 (35.4) 11 (21.2) 
Clinical signs d 0 a,b,c,d,e,f Mild 26 (19.9) 9 (14.1) 17 (25.4) 
 Severe 105 (80.1) 55 (85.9) 50 (74.6) 
Clinical signs d 2 c,d,e,f Mild 69 (62.2) 28 (48.3) 41 (77.4) 
 Severe 42 (37.8) 30 (51.7) 12 (22.6) 
Clinical cure on d 2 c,e,f Not-cured 109 (85.8) 57 (91.9) 52 (80.0) 
 Cured 18 (14.2) 5 (8.1) 13 (20.0) 
Frequent milking b,e No 54 (67.5) 25 (59.5) 29 (76.3) 
 Yes 26 (32.5) 17 (40.5) 9(23.7) 
Fluid therapy a,b,c,d,e,f No 90 (69.2) 38 (61.3) 52 (76.5) 
 Yes 40 (30.8) 24 (38.7) 16 (23.5) 
Treatment a,b,d,e  132 64 (48.5) 68 (51.5) 
Growth of E. coli b,f < 10 cfu/μL 11 (8.4) 4 (6.3) 7(10.3) 
 ≥ 10 cfu/μL 120 (91.6) 59 (93.7) 61 (89.7)  
Reinfection on d 21 No 53 (69.7) 28 (70.0) 25 (69.4) 
 Yes 23 (30.3) 12 (30.0) 11 (30.6) 
Categorical variable Level 
Frequency 
(%) g 
Enrofloxacin 
treated (%) 
Non-
treated (%) 
Parity a,e 1 26 (19.7) 10 (15.6) 16 (23.5) 
 2 46 (34.9) 23 (36.0) 23 (33.8) 
 ≥3 60 (45.4) 31 (48.4) 29 (42.7) 
Continuous variables  
Frequency 
(%) g Mean (SE)  
Days in milk e,f  100 125 (10.7)  
Enrofloxacin treated  51 (51.0) 110.4 (14.0)  
Non-treated  49 (49.0) 140.2 (16.3)  
NAGase activity d 0 
 (pmol 4-MU/min/μL)  a,c,d,e,f 112 16.21(0.72)  
Enrofloxacin treated  52 (46.4) 17.9 (1.0)  
Non-treated  60 (53.6) 14.8 (1.0)  
NAGase activity day 2 (pmol 4-MU/min/μL) d,e 94 21.1 (0.7)  
Enrofloxacin treated  46 (49.0) 24.0 (0.3)  
Non-treated  48 (51.0) 18.3 (1.3)  
a Variables with a P < 0.25 in the univariable analyses of bacteriological cure on d 2    
b Variables with a P < 0.25 in the univariable analyses of clinical cure on d 2  
c Variables with a P < 0.25 in the univariable analyses of clinical cure on d 21  
d Variables with a P < 0.25 in the univariable analyses of  NAGase activity on d 21  
e Variables with a P < 0.25 in the univariable analyses of returning of quarter milk production 
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f Variables with a P < 0.25 in the univariable analyses of remaining in a herd (Table 2 continues)  
g Total less than 132 for a whole variable means that data were missing 
1Number of herds was 61 and 132 cows were enrolled in the study. Cows were treated randomly 
with enrofloxacin or left untreated.  
 
On day 2, E. coli (n = 72), other coliforms (n = 2) and other bacteria (n= 5) were isolated in 72%, 
2% and 5% of the samples, respectively (n = 100; 32 missing data), while no bacterial growth was 
detected in 21% of the samples. In the enrofloxacin group, number of quarters positive for E. coli 
on day 2 was significantly lower than in the non-treated group (P = 0.002, odds ratio for 
bacteriological cure 3.32; Table 2). On day 21, E. coli, other coliforms, other bacteria and mixed 
growth were isolated 14.5%, 4.8%, 22.9% and 4.8% of the samples, respectively (n = 83, 49 
missing data). In 53.0% of the samples (44 out of 83) no bacterial growth was detected.  
 
Persistent E. coli infection, i.e., re-isolation of the original E.  coli pulsotype in the post-treatment 
sample on day 21, was detected in 9 quarters (11.3% of the 80 cases sampled at both occasions), 4 
of them in the enrofloxacin and 5 in the non-treated group. 
 
More severe signs on day 0 increased the risk of having E. coli growth in the milk sample on day 2 
(P = 0.02, odds ratio for cure 0.22). None of the tested factors affected bacteriological cure on day 
21 (n = 79 in the analyses).  
 
Enrofloxacin treatment decreased clinical cure on day 2 (P = 0.016, odds ratio 0.05), but use of 
frequent milking improved it (P = 0.005, odds ratio 39.82). Clinical cure was significantly more 
frequent on day 2 in cows that had milder systemic signs on day 0 (P = 0.002, odds ratio 0.25). 
Clinical cure on day 2 improved clinical cure on day 21 (P = 0.04, odds ratio 10.12). Bacteriological 
and clinical cure on day 21 in enrofloxacin and non-treated groups is depicted in Figure 6. 
 
Milk  NAGase  activity  on  day  21  was  associated  with  severity  of  the  clinical  signs  on  day  0;  the  
more severe signs, the higher NAGase activity on day 21 (P = 0.007). Only frequent milking was 
related to decreased milk NAGase activity on day 21 (P = 0.04). Enrofloxacin treatment did not 
decrease mammary gland tissue damage estimated using determination of milk NAGase activity 
(mean 10.37 pmol 4-MU/min/μl in the treated quarters and 7.71 pmol 4-MU/min/μl in the non-
treated quarters). 
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Figure 6. Bacteriological and clinical cure in acute clinical Escherichia coli mastitis on 
day 21 post-treatment after treatment with enrofloxacin (bacteriologically cured 37 of 43, 
clinically cured 28 of 60) or without treatment (non-enrofloxacin) (bacteriologically cured 
32 of 39, clinically cured 36 of 63). No significant differences were found between the 
treatment groups. 
 
Quarter milk production returned to the pre-infection level in 31 (29.3%) cows and diminished in 70 
(includes 31 cows with the blind quarter) (69.3%) cases (n = 101, 31 missing data). In the 
enrofloxacin group, quarter milk production returned in 21.8% (n = 12) of the cows and in the non-
treated group in 37.3% (n = 19). Enrofloxacin did not affect quarter milk production. Diminished 
quarter milk production or a blind quarter due to E. coli mastitis was found in 78.2% of the treated 
and in 62.8% of the non-treated cows. More severe clinical signs on day 0 impaired the return of 
quarter milk production (P = 0.02, odd ratio 16.2). The other variables had no effect on milk 
production. 
 
Three cows in the enrofloxacin group and five in the non-treated group (n = 132) did not survive 
(died or were euthanized) by day 21 post-treatment. All these cows were classified as severe cases 
on day 0. Of all cows, 31 (23.5%) (18 in the enrofloxacin group and 13 in the non-treated group; no 
significant difference) had left the herd during the six-month follow-up (Table 2). Enrofloxacin had 
no effect on remaining of the cows in the herd 6 months after treatment (71.9% of treated and 
80.6% of non-treated). 
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8.3. Characteristics of E. coli isolated from clinical mastitis (study III) 
 
The majority of initial 144 isolates, 119 (82.6 %), were found belong to phylogeny group A, 
followed by group D 16 (11.1%), group B1 7 (4.9 %) and B2 2 (1.4%). Of the 144 E. coli isolates, 
56 (38.9%) had at least one virulence factor gene detected by PCR (Table 3). The combinations of 
virulence genes varied greatly, and each combination was present mostly in one isolate only (Table 
3). Genes irp2, papC, iucD and iss were  the  most  common.  Genes  iucD, cva, iss and papC 
correlated together ((rφ=0.56-0.74). Only astA, eaeA, irp2 and genes for F17 were present alone; all 
other genes were detected in different combinations. Genes svg, stx1, stx2, cnf1 and hlyA were not 
found in any of the isolates. 
 
Of the initial 144 isolates, 40 (27.8%) showed resistance to one or more of the antimicrobials tested. 
In total 20.1% of isolates showed resistance to more than two antimicrobials. The most frequent 
resistances were for ampicillin (18.6%), streptomycin (16.4%), tetracycline (15.7%) and 
sulfametoxazol (13.6%). No resistance was found to gentamicin, florphenicol or ceftiofur (Table 4). 
Resistances to streptomycin, ampicillin, sulfametoxazol and trimethoprim were correlated with each 
other (rφ = 0.65-0.88). The virulence gene iucD was found to correlate with resistances to 
streptomycin, ampicillin, sulfametoxazol and trimethoprim (rφ = 0.60-0.81). None of phylogeny 
groups, virulence genes or resistances to antimicrobials had any association with the clinical signs 
of mastitis or milk NAGase activities. 
 
The same pulsotype of E. coli was isolated after 3 weeks from ten quarters of 85 sampled quarters 
(11.8%) reflecting the persistence of E. coli intramammary infection. Persistent isolates belonged to 
the  phylogenetic  group  A,  except  one  in  group  D.   One  of  the  persistent  strains  was  resistant  to  
seven different antimicrobials, six were susceptible to all antimicrobials evaluated. Four persistent 
strains were negative for all virulence genes studied. 
 
The clustering effect of the herd significantly affected the bacterial persistence (P = 0.03). The same 
pulsotype caused persistent mastitis in two different cows during 3 years on the same farm. This 
strain caused acute clinical mastitis episodes with severe clinical signs. None of the virulence 
factors, phylogeny groups or antimicrobial resistance traits was associated with the persistence of E. 
coli intramammary infection. 
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Table 3.  Combinations of virulence factor genes detected among initial isolates of E. coli.  
Virulence genes and their combinations Isolates 
astA eaeA     1 
astA irp2     2 
astA iucD     1 
sfaD papC irp2 vat   1 
sfaD papC irp2    1 
irp2 iss vat    1 
tsh cva iucD papC irp2 iss 1 
F17 irp2     1 
F17 irp2 iss CNF2   2 
AFA8 irp2 papC iucD   2 
AFA8 irp2 papC    1 
AFA8 papC irp2    1 
AFA8 iss irp2 papC iucD  3 
AFA8 iss irp2 papC iucD cva 3 
AFA8 saa CNF2    1 
cva iucD iss    3 
cva iucD iss irp2 papC  5 
cva papC iss irp2   1 
cva iucD papC irp2   1 
iucD iss     1 
iucD iss papC irp2   3 
iucD papC     1 
astA      6 
eaeA      1 
F17      3 
irp2      10 
Negative      88 
Total 
number           144 
 
Table 4. Distributions of MICs for E. coli from bovine mastitis (n = 144). MICs equal to or lower than the lowest concentration tested 
are given as the lowest concentration. Numbers of resistant isolates for each antimicrobial tested are indicated with gray fields. 
n = 144 
MIC (%) 
distribution mg/l                 
Antimicrobial 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
Resistant 
(%) 
Ampicillin      2 23 57 27 8 1   26      18.7 
Streptomycin         18 84 16 2 1 5 9 9   18.1 
Tetracycline       36 80 4   3 6 15     16.7 
Sulphametoxazol           119 4      21 14.6 
Trimethoprim     35 63 28 3     15      10.4 
Cloramphenicol        2 78 54     10    6.9 
Kanamycin        7 108 20  9       6.3 
Cefotaxime   96 32 13 1 2            1.4 
Nalidixin acid       2 57 80 4     1    0.7 
Ciprofloxacin 12 71 60   1             0.7 
Gentamicin      12 106 24 2          0 
Florphenicol        2 43 92 7        0 
Ceftiofur   1 1 51 87 4            0 
 
 8.4. The efficacy of lactoferrin in the treatment of experimental E. coli 
mastitis (study IV) 
 
In this experimental model, all cows were infected and developed clinical mastitis, which tended to 
be milder for the second challenge. Differences in systemic and local signs (Figure 7) between Lf- 
and enrofloxacin treated cows were not statistically significant. 
 
Bacterial counts in milk decreased more rapidly in enrofloxacin- than Lf-treated cows, the 
difference almost reaching significance (P = 0.054) (Figure 7). After the second challenge, three 
cows had very low bacterial counts in the milk before the first enrofloxacin treatment at the first 
sampling 12 hours PC. The average bacterial counts are shown in Figure 7. 
 
 Figure 7. Scores for mean (± SEM) local signs, total daily milk production, milk NAGase 
activity of the infected quarter and milk bacteriological counts for the lactoferrin (Lf) and 
enrofloxacin (Enro) treated cows with experimentally induced E. coli mastitis. Challenges 
were carried out 3 weeks apart in six cows. 
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The  corresponding  ratios  of  the  concentration  of  LPS  to  the  number  of  bacteria  in  milk  for  the  
enrofloxacin- and Lf-treated cows were 3.7 × 10-1 and 2.6 × 10-4, the difference being statistically 
significant (P = 0.028). Milk NAGase activity remained high for a significantly longer time in cows 
treated with Lf than in milk of enrofloxacin-treated cows (P = 0.046) (Figure 7).  
 
 
8.5. Experimental E. coli mastitis in rhLf-transgenic cows (study V) 
 
All cows in the rhLf-group (transgenic) and in the control group became infected and developed 
clinical mastitis within 8-12 hours PC. The transgenic cows developed significantly less severe 
clinical signs compared with the control cows (P = 0.020). The transgenic group recovered 
significantly faster than the control group (P = 0.008). All transgenic cows and five cows in the 
control group showed mild to moderate systemic signs, and only one cow in the control group 
showed a  severe  reaction.   Systemic  signs  of  all  cows  in  the  transgenic  group returned  to  normal  
within 24 hours, while the recovery of the control cows was slower and lasted over 48 hours. The 
local signs of the infected quarters and changes in the appearance of milk disappeared within 7 days 
PC in both groups (Figure 8). Expression levels of rhLf remained relatively constant during the 
experiment and rhLf concentrations in the milk ranged in the milk from 2.35 to 2.89 mg/ml, while 
bLf showed marked increase in both groups (Figure 9). 
 
Milk  bacterial  counts,  concentrations  of  SAA and Hp,  SCC and NAGase  activities  did  not  differ  
statistically between the groups (Figure 10). All cows showed local and systemic TNF-α response. 
A concentrations of TNF-α in the milk were higher than concentrations in serum in both groups. 
The difference between the groups was not significant. All cows showed increased serum cortisol 
concentrations (Figure 11). The difference in serum cortisol concentrations between the groups was 
significant at 8, 36 and 168 hours PC (P = 0.003, P = 0.031, P = 0.048).  
 
The mean values of serum SAA and Hp are shown in Figure 11. The difference between the groups 
was significant only at 8 (P = 0.035) and 168 hours PC (P = 0.029). No differences were noted in 
serum concentrations of AFOS, ALAT, total protein, urea, creatinine, and albumine, or in the WBC 
or PVC values between the groups.  
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Figure 8. Rectal temperature (a) and local signs (b) in transgenic (◊) and control (■) cows 
in experimental E. coli mastitis. Data are presented as means ± SEM for six transgenic 
and five control cows. 
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Figure 9. Mean concentrations of rhLf (♦) and bLf (◊) in the milk in challenged udder 
quarters of transgenic cows and of bLf (■) in milk from control cows in experimental E. 
coli mastitis. Data are presented as means ± SEM for six transgenic and five control cows. 
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Figure 10. Mean (a) bacterial counts, (b) milk SAA levels, (c) milk SCC, and (d) Hp 
concentrations in milk from transgenic (◊) and control (■) cows during the experiment. 
Data are presented as means ± SEM for six transgenic and five control cows. 
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Figure 11. Mean serum (a) TNF-α, (b) cortisol, (c) SAA, and (d) Hp concentrations in 
transgenic (◊) and control (■) cows in experimental E. coli mastitis. Data are presented as 
means ± SEM for six transgenic and five control cows. The P values indicated in panel b 
are 0.003 (*), 0.031 (**), and 0.048 (***) for cortisol, and those in panel d are 0.035 (*) 
and 0.029 (**) for serum Hp.   
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9. DISCUSSION  
 
9.1. Pathogenesis of E. coli mastitis 
 
Host responses and the clinical course of experimentally induced E. coli mastitis have been 
described in many previous studies (Hill et al., 1978; Pyörälä et al., 1994; Shuster et al., 1996; 
Shpigel et al., 1997; Hirvonen et al., 1999; Hoeben et al., 2000a; Rantala et al., 2002). E. coli 
intramammary infection typically results in acute clinical mastitis. The course of the disease varies 
from mild with only local signs in the udder to very severe or even fatal. Local signs and possible 
general signs, such as fever, increased heart rate, depressed rumen motility, inappetite and 
depression, gradually become appearant. The first clinical signs are detected in the affected quarter 
8 h post-challenge and general signs by 12 h (Lohuis et al., 1990; Hirvonen et al., 1999; Hoeben et 
al., 2000a; Kornalijnslijper et al., 2004). Milk SCC dramatically increases in the mastitic quarter. 
Milk  production  decreases  or  is  completely  lost  in  the  affected  quarter,  and  in  severe  cases  milk  
production ceases in all four quarters (Vandeputte-Van Messom et al., 1993; Kornalijnslijper et al., 
2004). In mild or moderate cases, general signs disappear within two days and local signs by one 
week (Hill et al., 1978; Lohuis et al., 1990; Hirvonen et al., 1999; Hoeben et al., 2000a; 
Kornalijnslijper et al., 2004). In severe cases the cow may become recumbent and die (Hirvonen et 
al., 1999; Rantala et al., 2002). 
 
This thesis is based on the results of three separate studies using an experimentally induced E. coli 
mastitis model (study I, IV and V). The development of infection and clinical course of the disease 
were quite similar in all the studies, and also similar to the previously described studies. The 
majority of the cows had mild or moderate mastitis  and recovered within a week after the E.  coli 
challenge.    
 
In the study using S. aureus as the challenge organism, repeated intramammary inoculation at an  
interval  of  four  weeks  in  the  same  cows  revealed  possible  carry-over  effects  of  the  previous  
intramammary infection by the same pathogen (Eckersall et al., 2006), but only a tendency towards 
elevated concentrations of APP was recorded. Hirvonen et al. (1999) did not find stronger systemic 
acute phase respons after a second intramammary challenge with E. coli within a shorter interval of 
three weeks.  In study I of this thesis, using two consecutive intramammary challenges with E. coli 
two weeks apart, all cows at both times became infected and developed local and systemic 
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inflammatory reactions, but after the second challenge local signs were significantly milder and 
disappeared faster. Milk production returned to the pre-challenge level significantly faster after the 
second challenge. The same pattern was noted for the indicators of inflammation evaluated, 
indicating a clear carry-over effect from the first challenge.  In another experimental challenge 
study included in this thesis (study IV) we also detected rapid elimination of bacteria after the 
second challenge in three cows, which similarly reflected a carry-over effect. In that study, the 
interval between challenges was three weeks. 
 
In previous studies using an experimentally induced E. coli mastitis model and 3 week interval, the 
disease was slightly milder after the second challenge, but the differences were not statistically 
significant (Pyörälä et al., 1994; Rantala et al., 2002; Kutila et al., 2004). Sensitization of the 
mammary gland after the first contact with a moderate dose of LPS was observed in the study with 
repeated challenges with LPS at a 24 h interval (Rainard and Paape, 1997). They did not detect 
systemic signs after the first LPS challenge, which was suggested to be due to too small an amount 
of  LPS to  trigger  a  systemic  response,  but  after  the  second infusion,  24  hours  later,  the  systemic  
signs were apparent. Relatively large doses of live E. coli were used in our study with a much 
longer interval (2 weeks), which resulted in significant changes in inflammatory response. 
 
Recognition of LPS is an important event in the activation of the innate immune response to Gram-
negative bacteria. LPS directly interacts with neutrophils through CD14, which is expressed on cell 
surfaces (Paape et al., 2003). The effective removal of the bacteria by neutrophils is important for 
the elimination of the infection. If delayed, infection can lead to development of endotoxin shock 
(Burvenich et al., 2003). Some immunization effect could have occurred in our study, which 
resulted in a faster host response and milder disease, as well as rapid elimination of bacteria from 
the infected gland after prior inoculation of a different quarter. In developing immunological 
memory for improving host defense, B-cells change from production of IgM to other antibody 
isotypes, in particular IgG1 and IgG2 (Burton and Erskine 2003). Vaccination with a core antigen 
(E. coli J5) promoted production of more IgG2 at early stages of the intramammary infection, which 
probably increased phagocytosis by PMN and elimination of bacteria (Wilson et al., 2007b). 
Repeated infections caused by the same bacterial species could trigger a vaccination effect, i.e. 
result in faster elimination of bacteria and decreased severity of the clinical signs because of the 
immunological memory of the cow. However, Schukken et al. (2009) did not find evidence for this 
in their field study on repeated cases of mastitis caused by the same bacterial group. The milk loss 
reflecting clinical signs was the same during the first, second and third episode of mastitis caused 
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by Gram-negative bacteria during the same lactation period. The mean interval between mastitis 
episodes  in  that  study  was  about  two months.  If  some vaccination  effect  ever  was  present,  it  had  
waned by that time. The duration of the effect of the common core vaccine has been reported to be 
approximately 2.5 months (Wilson et al., 2009). The vaccine antigens should provide protection 
against all Gram-negative mastitis causing species. Schukken et al. (2009) grouped the bacteria into 
Gram-negative and Gram-positive classes, without going to species level, which may have affected 
their results. In our study, the consecutive challenges were done with the same bacterial strain. A 
protective effect was apparent, but according to other experimental studies (Hirvonen et al. 1999; 
Kutila et al. 2004; Rantala et al., 2002) it would last about 3 weeks and not longer. The route of 
immunization affects the development of the immune response of the host, and intramammary 
challenge certainly differs from systemic administration of antigens. 
 
Only few studies have reported concentrations of acute phase proteins in the milk during 
experimentally induced E. coli mastitis. In the study of Jacobsen et al. (2005), with a lower dose (50 
cfu) of E. coli, concentrations of SAA in plasma were at a similar level, but those in the milk were 
5-times as high as recorded in our study. Milk concentrations of SAA were highest in cows with 
severe mastitis but did not differ between those with moderate or mild signs (Jacobsen et al., 2005). 
Concentrations of mammary-derived SAA in milk were many times higher than concentrations of 
SAA in serum in their study and in ours. SAA has been suggested to have an important role in the 
modulation of the host response during infection (Patel et al., 1998; Vallon et al., 2001). SAA is 
able to bind outer membrane protein A of E. coli, which may also contribute to the recognition of 
Gram-negative bacteria by the host (Hari-Dass et al., 2005). Rapid mammary SAA response is 
probably involved in the innate local protection against pathogens invading the udder.  
 
In our two experimental studies (study I and V), concentrations of Hp in the milk were similar. In 
the study of Hiss et al. (2004), using LPS challenge, the concentrations of Hp in milk increased by 
the end of the 12 h follow-up period and were less than half the concentrations recorded here. In our 
studies and in the cited study where an ELISA assay was used (Hiss et al., 2004), the concentrations 
of Hp in milk were approximately half those in serum. The Hp assay used in our studies has not 
been validated for milk and the results should be interpreted with caution. The local production of 
Hp seems not to be so pronounced as that of SAA. Hp binds harmful molecules produced after 
tissue  damage,  such  as  hemoglobin,  which  then  becomes  inaccessible  to  bacteria  and  limits  their  
growth (Baumann et al., 1994). With this function, Hp may complete the actions of Lf (Hiss et al., 
2004) and may thus play a role in host defense against E. coli mastitis.   
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LBP is a relatively new acute phase protein in the cow, and Bannerman et al. (2003) first reported 
concentrations of LBP in milk. Concentrations of LBP in milk and plasma have been shown to 
increase after intramammary challenge with LPS (Bannerman et al., 2003) and E. coli (Bannerman 
et al., 2004; Vangroenweghe et al., 2004). Concentrations of LBP in blood and milk found in our 
study (study I) are higher than reported in the previous studies using E. coli challenge models 
(Bannerman et al., 2004; Vangroenweghe et al., 2004). In our study (study I), concentrations in the 
milk were higher than those in blood, contrary to the findings of Bannerman et al. (2004). 
Challenge models and other methods used may be different, which could partly explain differences 
between results from different studies. LBP is a hepatocyte-derived protein that binds LPS, 
enhances LPS-CD14-complex formation and increases the sensitivity of the host’s innate response 
to Gram-negative bacteria (Wright et al., 1990; Burvenich et al., 2007; Le Roy et al., 2001). It is 
possible that LBP is also produced locally by the mammary epithelial cells, as also suggested by 
Bannerman et al. (2003), which would explain the high concentrations in the milk recorded in our 
study.   
 
Lf is believed to act as a LPS-binding protein during the inflammatory activation of macrophages 
(Na et al., 2004). Lf competes with LBP for binding to LPS and might interfere with the interaction 
of LPS with CD14 (Legrand et al., 2004). LBP and CD14 are known to enhance LPS-induced host 
cell activation and to facilitate detoxification of LPS, preventing this response from becoming 
excessive and harmful to the host itself (Bannerman et al., 2003). The LPS-neutralizing activity of 
Lf may depend on the presence and concentration of other LPS-binding proteins.  
 
The  concentrations  of  SAA and Hp in  serum and milk  in  this  E. coli infection model were much 
higher than those reported in experiments using Gram-positive pathogens (Eckersall et al., 2006), 
indicating the strong inflammation induced by E. coli. We used one dose of anti-inflammatory 
medication at 12 h PC in our study (study I), which may slightly affect the inflammatory response, 
but  given  at  both  challenges,  allows  comparison  of  the  two  subsequent  challenges.  Use  of  acute  
phase proteins as early markers of mastitis has been suggested. They would also be useful 
parameters to monitor the severity of mastitis, to be used in studies on pathogenesis and effect of 
treatments.  
 
Pathogenesis of E. coli mastitis and immunological mechanisms of the mammary gland deserve 
more  research.  Experimental  models  are  available,  and  they  do  not  necessarily  have  to  be  bovine  
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(Gonen et al., 2007). Repeated experimental intramammary induction of the same animals with E. 
coli bacteria has been used as a model in crossover studies to reduce the individual variation 
between cows, but cow models are expensive and group size is limited. If cow-models are used for 
crossover studies, the significant differences between the consecutive challenges seen here suggest 
that in these studies the interval between challenges should be longer than 2 weeks. 
 
9.2. E. coli mastitis therapy   
9.2.1. Antimicrobial treatment 
The role of antimicrobials in the treatment of E. coli mastitis is still open to debate. Clinical signs 
are mainly caused by LPS and treatment should be targeted towards these effects. On the other hand 
growing bacterial populations produce increased amounts of LPS, and consequently, infection 
contributes to the effects of LPS. Spontaneous elimination of intramammary infection with E. coli is 
generally high (Anderson 1989; Erskine 1991). In some field studies on clinical mastitis caused by 
coliform or E. coli bacteria, antimicrobial treatment has offered some advantages (Morin et al., 
1998; Poutrel and Dellac, 2004), but many have shown no beneficial effects (Jones and Ward, 1990; 
Guterbock et al., 1993; Pyörälä and Pyörälä, 1998; Erskine et al., 2002; Sérieys et al., 2005). In 
some field studies equal cure rates of E. coli mastitis have been the same using antimicrobials active 
or inactive against coliforms in vitro (Jones and Ward, 1990; Pyörälä and Pyörälä, 1998). Most, if 
not all, published field trials have not been designed as prospective studies to determine the efficacy 
of defined antimicrobial treatment in E. coli mastitis, but have used retrospective data. They lack an 
untreated control group, and mostly do not include a species-specific diagnosis. Susceptibility 
testing of the causal bacteria to the antimicrobial used has been tested only seldom, and when 
performed, the methods have not been properly described. Without knowledge on the susceptibility 
of the causal bacteria to the antimicrobial agent used, a critical assessment of the treatment outcome 
is difficult. In experimental studies in which the conditions can be controlled, some advantage from 
antimicrobial treatment over no treatment has been shown, such as faster elimination of bacteria, 
prevention of death of the cows, or reduction of the loss of milk production (Shpigel et al., 1997; 
Hoeben et al., 2000; Rantala et al., 2002; Poutrel et al., 2008). 
 
In severe coliform mastitis, a substantial proportion of the cows, about 30%, has been reported to 
develop  bacteremia  (Cebra  et  al.,  1996;  Wenz  et  al.,  2001b).  In  the  earlier  study  of  Powers  et  al.  
(1986) only Bacillus sp was isolated in cultured blood samples from cows with acute coliform 
mastitis and attributed to skin contamination. In the study of Pyörälä et al. (1994) on experimental 
 58
E. coli mastitis, no bacteremia was detected. Based on the results from the field studies, systemic 
administration of antimicrobials has been recommended for the treatment of coliform mastitis 
(Cebra et al., 1996; Wenz et al., 2001b; Erskine et al., 2003). The field studies on bacteremia in E. 
coli mastitis, as well as the recommendations based on them, originate from the United States, and 
their applicability to other conditions requires confirmation. Systemic administration of 
antimicrobial used is the only route to treat bacteremia (Constable et al., 2008). Another advantage 
of the systemic route is that antimicrobials penetrate better into the udder tissue, in particular in 
clinical mastitis, when the udder can be swollen and hard (Ziv 1980).  
 
The selection of antimicrobials available for systemic treatment of coliform mastitis in dairy cows 
differs among countries. For example, in the United States, fluoroquinolones are not approved for 
treating dairy cows. Few antimicrobials have favourable pharmacokinetic and pharmacodynamic 
properties for treatment of acute clinical mastitis (Erskine et al., 2003; Constable et al., 2008). 
Broad-spectrum antimicrobials, such as fluoroquinolones, cefquinome, ceftiofur, and 
oxytetracycline, have been tested and recommended for treatment of E. coli mastitis (Shpigel et al., 
1997; Cebra et al., 1996; Erskine et al., 2002; Morin et al., 1998; Wenz et al., 2001b).   
 
Fluoroquinolones are recommended for treatment of severe E. coli mastitis in dairy cows in Finland 
as the first choice and high doses of trimethoprim-sulphonamides as an alternative (Evira 2009). 
Milk disturbs the activity of trimethoprim-sulphonamides (Fang and Pyörälä, 1996), and therapeutic 
concentrations of this combination are difficult to achieve and maintain in the milk (Kaartinen et al., 
1999). Phagocytic activity is decreased in the infected mammary gland and bactericidal 
antimicrobial agents would be preferable over bacteriostatic agents, the efficacy of which depends 
to a greater extent on the level of host defense (Kehrli and Harp, 2001). The trimethoprim-
sulphonamide combination can be bactericidal in some concentration ranges, but probably not in the 
bovine udder where pharmacodynamic conditions are far from optimal (Pyörälä et al., 1994; 
Wagner and Erskine, 2006). 
 
Oxytetracycline  is  an  antimicrobial  substance  used  for  treatment  of  E. coli mastitis (Morin et al., 
1998). The efficacy of oxytetracycline in the treatment of E. coli mastitis has not been proven 
(Constable and Morin, 2003). Antibacterial activity of tetracycline is reduced in milk because of 
chelate formation of tetracycline with casein (Fang and Pyörälä, 1996). In a recent study the 
increase of MIC of E. coli isolated from mastitis to oxytetracycline was reported to be over 16-fold 
in raw milk as compared with conventional growth media (Kuang et al., 2009). The doses suggested 
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for treatment of coliform mastitis (5-20 mg/kg) are too low to achieve and maintain therapeutic 
concentrations  in  the  milk  when  only  the  free  part  of  the  drug  is  active.  The  breakpoint  
concentration for susceptibility of E. coli to tetracycline is 8 μg/ml (FINRES-Vet 2005-2006), 
which is hardly reached even in serum, and only after i.v. administration (Pharmaca Fennica 
Veterinaria 2010). The concentration of oxytetracyclin in milk after administration of 10 mg/kg is 
about 1.9 μg/ml 10 h after systemic administration, which is far from the therapeutic concentration 
(Erskine et al., 2003). 
 
A  third  generation  cephalosporine,  ceftiofur,  is  authorized  for  treatment  of  respiratory  disease  in  
cattle with a dose of 1 mg/kg (Pharmaca Fennica Veterinaria 2010). It diffuses poorly to milk and 
does not have a withdrawal time for milk (Prescott 2006). Ceftiofur administered at 3mg/kg every 
12 h failed to eliminate bacteria in experimental E. coli mastitis (Erskine et al., 1995). Ceftiofur was 
not  detectable  in  milk  of  healthy  cows,  but  could  be  detected  in  milk  of  challenged  cows,  with  a  
maximum concentration of 0.28 μg/ml (Erskine et al., 1995). This concentration could be, in theory, 
be enough for susceptible E. coli bacteria. For naturally occurring coliform mastitis, systemic 
ceftiofur therapy with a dose of 2.2.mg/kg/day intramuscularly for five days, was shown to 
favourably influence the clinical outcome of severe cases of coliform mastitis (Erskine et al., 2002). 
Using ceftiofur for treatment of mastitis is off-label and should be avoided; the dose used is also 
higher than the label dose and the zero withdrawal time for milk is then not applicable. 
 
The fluoroquinolones danofloxacin and enrofloxacin are authorized for lactating cattle in the 
European  Union,  and  are  also  used  for  treatment  of  coliform  mastitis  (Poutrel  and  Dellac,  2004;  
Poutrel at al., 2008; Constable et al., 2008). Mastitis is not an approved indication for danofloxacin 
in most EU countries; also the common label dose, 1.25 mg/kg, appears low for mastitis treatment 
(Pharmaca Fennica Veterinaria 2010). In Sweden, danofloxacin has recently been approved for 
treatment of coliform mastitis at a higher dose level, 6 mg/kg (FASS 2010). Enrofloxacin is one of 
the few antimicrobial drugs, that have been recommended for the treatment of coliform mastitis, 
due to its favorable pharmacokinetic and pharmacodynamic properties (Constable et al., 2008). 
Enrofloxacin has reported to increase the killing capasity of neutrophils (Hoeben et al., 1997), 
which may contribute to its therapeutic effect. However, the influence of fluoroquinolones on PMN 
activity and function is controversial (Labro 2000). The antimicrobial activity of enrofloxacin is not 
reduced in milk (Fang and Pyörälä, 1996). All isolates in our field study (study II) were susceptible 
in vitro to ciprofloxacin, which is the active metabolite of enrofloxacin. High ciprofloxacin 
concentrations are reached in blood and milk (Kaartinen et al., 1995; Rantala et al., 2002). Here we 
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used the higher label dose of 5 mg/ml, which should maintain the therapeutic concentrations in the 
milk (Rantala et al., 2002). Despite this, in our field study systemic enrofloxacin treatment did not 
result in better bacteriological or clinical cure of acute clinical mastitis caused by E. coli than 
supportive treatment alone. Neither did enrofloxacin treatment affect survival of the cows, returning 
of quarter milk production or tissue damage of the infected quarter. The only positive effect of the 
enrofloxacin treatment was the better bacteriological cure on day 2 post-treatment, although, 
clinical  cure  on  day  2  was  significantly  lower.  The  clinical  relevance  of  these  findings  on  day  2  
appears minor, as the final outcomes from mastitis assessed 3 weeks post-treatment did not differ. 
For the farmer, the outcome of the greatest economic importance is the return of the quarter to 
producing milk acceptable for delivery.  
 
Faster elimination of bacteria from the quarter was reported in cows treated with enrofloxacin than 
in non-treated cows in an experimental E. coli mastitis model (Rantala et al., 2002). Furthermore, in 
experimentally induced E. coli mastitis, enrofloxacin treatment significantly decreased the milk loss 
determined 2 days post-treatment and alleviated local signs in the affected quarter after 24 hours 
post-treatment (Hoeben et al., 2000b). Poutrel et al. (2008) tested another fluoroquinolone, 
danofloxacin, also using an experimental E. coli model and reported that the initial clearance of 
bacteria from the quarters was faster in the danofloxacin group, but the final bacteriological cure 
was  similar  as  in  the  untreated  group.  Our  results  from  the  field  study  (study  II)  on  the  better  
bacteriological cure on day 2 thus agree with these experimental studies, but the clinical cure on day 
2 was significantly lower in the enrofloxacin-treated than in non-treated cows, and  the clinical cure 
on day 21 was slightly inferior compared with that for the untreated cows. In theory, this could due 
to release of endotoxin after the more efficient killing of bacteria by enrofloxacin. In humans, the 
release of endotoxin from dead Gram-negative bacteria after antimicrobial treatment is considered a 
risk for endotoxin shock (Lepper et al., 2002), a finding that supports this theory. However, 
Dosogne et al. (2002a) showed that concentrations of endotoxin in the plasma did not differ in 
enrofloxacin-treated and untreated cows. In support of this, no differences in the concentrations of 
endotoxin in the milk were found for cows with experimentally induced E. coli mastitis treated with 
antimicrobials or left untreated (Pyörälä et al., 1994). Therefore, the theory of excessive release of 
endotoxin in the treated group is not supported. Clinical cure on day 21 (Figure 6) was rather low in 
both treatment groups, which probably reflects the severe nature of E. coli mastitis. Katholm & 
Andersen (1998) reported similar proportions of clinical and bacteriological cure from a Danish 
field study on E. coli mastitis with no antimicrobial treatment, but no control group was included in 
their study. Contrary to our findings, danofloxacin reduced decrease in the milk production and 
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lowered SCC and udder inflammation scores assessed 3 weeks post-treatment (Poutrel et al., 2008). 
Enrofloxacin did not affect returning of quarter milk production evaluated at 3 weeks post-treatment 
in our study, Discrepant results may be explained by the different nature of the experimental and 
field studies.  
 
Milk SCC can remain high for a long time after E. coli mastitis  (Pyörälä  and  Pyörälä,  1997)  and  
such quarters often develop new infections caused by other bacteria. In our study (study II) 30% of 
quarters were infected by other bacteria three weeks after E. coli mastitis developed. This could be 
because mastitic milk has been shown to be a better growth medium for mastitis bacteria than milk 
from healthy quarters (Mattila et al., 1984). 
 
The proportion of died or euthanized cows after coliform mastitis was reported to be approximately 
25% in the United States (Cebra et al., 1996; Wenz et al., 2001b). This was much higher than our 
corresponding figure of 6%. The follow-up period in the former U.S. study was 4 weeks compared 
to our 3 weeks, and they included all cows culled during the study period. Furthermore, the U.S. 
study was carried out in a teaching hospital clinic, which could indicate that many cows with severe 
disease were included in the material, explaining the high fatality rate. Factors including cow breed, 
milk yield, management, environment and herd size may also explain the differences. E. coli 
mastitis is known to cause a long-lasting decrease in milk production of the affected quarter 
(Golodetz et al., 1983), milk SCC remains easily high (Pyörälä and Pyörälä, 1997) and milk is not 
accepted for marketing. The proportion of cows removed from the herd within 6 months in our 
study was 23.5%, indicating a high risk for a cow to be culled after E. coli mastitis. Bar et al. (2008) 
showed that clinical mastitis increased the odds of a cow dying or being sold for slaughter, thereby 
supporting our findings. In our study, remaining in the herd and DIM were significantly associated, 
indicating  that  a  cow  was  more  likely  to  be  kept  in  the  herd  if  it  was  in  late  lactation  and  
approaching drying-off. This was in contrast to findings that culling rates after clinical mastitis were 
increased in later-lactating cows (Gröhn et al., 2005; Bar et al., 2008). Those studies were carried 
out in the United States, possibly reflecting management differences for large dairy herds. In the 
smaller, family-owned herds of Finland, cows are managed more individually, which may explain 
differences in culling policies.  
  
Our results indicate that antimicrobial treatment is not needed in acute clinical mastitis caused by E. 
coli if  the  clinical  signs  are  mild  or  moderate.  Enrofloxacin  treatment  did  not  affect  the  outcome 
from mastitis, not even in severe cases. This means that at least in mild and moderate acute clinical 
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mastitis, routine use of broad-spectrum antimicrobials is not necessary, and the treatment can be 
targeted towards the common Gram-positive mastitis bacteria (Constable 2008). Rapid diagnostic 
tools to differentiate among coliform and other types of mastitis causing agents would be useful. 
The only cow-side test developed for this purpose, based on detection of endotoxin (Waage et al., 
1994), is no longer available. Targeting the antimicrobial treatment of mastitis towards Gram-
positive bacteria and using a non-antimicrobial approach for coliform mastitis has been suggested 
as a routine procedure for herds (Bennedsgaard et al., 2010; Lago et al., 2009). 
 
Antimicrobial therapy can reduce the number of bacteria at the acute stage of infection in severe 
mastitis and provide time for the immune system to act. In the study using a severe experimental E. 
coli mastitis model by Rantala et al. (2002), enrofloxacin treatment appeared to prevent death of the 
cows. In peracute or severe acute E. coli mastitis, the potential risk of increasing bacterial counts in 
the  milk  and  development  of  bacteremia  support  the  use  of  antimicrobials  to  save  the  life  of  the  
cow. If the number of E. coli bacteria  in  the  milk  is  very  high,  the  prognosis  for  the  cow is  poor  
(Katholm and Andersen, 1992; Vandeputte-Van Messom et al., 1993; Katholm and Andersen, 
1998).  The  bacterial  count  in  the  initial  sample  could  represent  a  valuable  tool  for  a  cattle  
practitioner in to evaluate the prognosis of the cow and possible need for antimicrobial treatment 
could be (Vandeputte-Van Messom et al., 1993; Hirvonen et al., 1999; Katholm and Andersen, 
1998). Katholm (2003) has suggested that there is no need for antimicrobial treatment in E. coli 
mastitis if the bacterial count in the milk is low, i.e. only single colonies and no carpet growth is 
detected on the agar plate. Nevertheless, in cases of severe acute mastitis, it is recommended to start 
treatment with antimicrobials on the basis of the clinical signs before the bacteriological diagnosis. 
In  severe  cases  of  E. coli mastitis, tissue damage may, however, be too grave for antimicrobial 
treatment to offer any significant benefit (Hill 1984; Vandeputte-Van Messom et al., 1993). 
  
Fluoroquinolones are important antimicrobials for the treatment of severe and invasive infections in 
humans and animals. They are of special interest for public and animal health (Collignon 2009). 
The development of the antimicrobial resistance among some species of bacteria has been alarming 
(White 2006). Fluoroquinolones should only be used for severe infections and when their efficacy 
has been confirmed (EMEA 2006). Antimicrobial residues in the tissues and milk of the treated 
cows are one reason for concern about antimicrobial therapy. Fluoroquinolone residues are not 
necessarily detected by the current tests for antimicrobial residues in the milk (Pyörälä 2009). 
Mastitis treatments should be evidence-based, i.e. the efficacy of all treatments should be 
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demonstrated by scientific studies, and this is particularly critical for reserve antibiotics (Cockcroft 
and Holmes, 2003). 
 
9.2.2. Non-antimicrobial therapy  
Non-steroidal anti-inflammatory drugs (NSAID) are commonly used and recommended for 
treatment of coliform mastitis (Katholm and Andersen, 1992; Green et al., 1997; Erskine et al., 
2003; Huxley 2004; Leslie et al., 2010). NSAIDs possess anti-inflammatory, antipyretic, and 
analgesic properties (Smith 2005). As discussed earlier, in cases of mild and moderate E. coli 
mastitis the emphasis of treatment should be focused on supportive therapy, and not on 
antimicrobial treatment. In severe cases of mastitis, the presumptive diagnosis of coliform mastitis 
can be based on clinical signs, systemic disease signs in particular, such as rectal temperature, 
rumen contraction rate, hydration status and signs of depression (Wenz et al., 2001a). Correction of 
dehydration using fluid therapy is usually, if not always, indicated in severe cases of coliform 
mastitis with orally administered or i.v. administered hyper- or isotonic saline (Smith 2005). 
Mastitis is a painful condition and cow welfare and relief of pain should be taken into account 
(Leslie et al., 2010). The efficacy of NSAIDs has been shown in revealing clinical signs and 
diminishing effects of endotoxin (Shpigel et al., 1994; Pyörälä and Syväjärvi, 1987; 
Vangroenweghe et al., 2005; Banting et al., 2008). Several NSAIDs are authorized for dairy cows in 
the  EU for  the  indication  of  treatment  of  mastitis.  Meloxicam,  for  example,  has  been  reported  to  
have a longer-acting effect, approximately 48 h, of reduction of pain in the quarter and decreasing 
in heart and respiratory rates in an endotoxin mastitis model (Banting et al., 2000).     
 
Systemic administration of glucocorticoids has previously been used and recommended for 
treatment of coliform mastitis (Anderson and Hunt, 1989; Erskine et al., 2003). They are considered 
to  decrease  the  effects  of  endotoxemia  and  reduce  the  clinical  signs,  but  a  negative  effect  is  that  
they suppress the neutrophil migration to the infection site (Diez-Fraile et al., 2002; Erskine et al., 
2003; Burton and Erskine, 2003). If these drugs are used, it should be only for severe cases of 
mastitis  (Erskine  et  al.,  2003).  NSAIDs  are  considered  more  effective  than  glucocorticoids  in  
alleviating clinical signs associated with endotoxemia in cattle (Smith 2005), although controlled 
studies comparing these two classes of substances in mastitis models are very few (Wagner et al. 
2004).  
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Frequent milking is a traditional treatment for mastitis and is commonly recommended as a 
supportive treatment for clinical mastitis (Radostits et al., 2007). Studies on its efficacy in treating 
severe experimental E. coli mastitis have furnished contradictory results, as both advantageous 
effect and no benefits have been shown (Stämpfli et al., 1994; Leininger et al., 2003). The results of 
experimentally induced E. coli mastitis model indicated that frequent milking as a treatment did not 
improve outcome nor did it appear to have negative effect (Leininger et al., 2003). Results from our 
field data (study II) indicated that frequent milking at the acute stage of mastitis can improve the 
initial clinical cure of E. coli mastitis. It is possible that frequent milking decreased inflammation 
and limited tissue damage in the infected quarter. In our study, the number of observations was 
quite small, which reduces the statistical power. Frequent milking is laborious and seldom 
applicable in the modern large dairy herds, but if done, can offer some benefits for the individual 
cow.  
 
Several other non-antimicrobial approaches to mastitis treatment have been investigated. For 
example, herbal remedies and homeopathy are without effect (Hektoen et al., 2004; Tikofsky and 
Zadoks, 2005). Antimicrobial proteins, such as nisin and lysostaphin, cytokines, and recombinant 
soluble CD14, have been investigated under experimental conditions for the treatment of acute 
mastitis, but have provided no evidence of practical benefits (Sears et al., 1995; Bramley and 
Foster, 1990; Lee et al., 2003). Lactoferrin is one of the non-antimicrobial substances tested against 
mastitis bacteria in vitro and in vivo. Synergistic effects of the combinations of Lf and 
antimicrobials have been reported for Gram-positive bacteria (Sanchez and Watts, 1999; Diarra et 
al., 2002; Komine et al., 2006; Lacasse et al., 2008). The research in this treatment area has 
concentrated on staphylococcal mastitis. Early studies showed that Lf inhibited bacterial growth by 
the acquisition of essential iron from the environment of the bacteria, whereas more recent findings 
have indicated wider interactions with bacterial cells (Bellamy et al., 1992; Lönnerdal and Iyer, 
1995; Legrand et al., 2004). When Lf affects Gram-negative bacteria, there is a concomitant release 
of LPS, after which Lf can inhibit its detrimental effects (Yamauchi et al., 1993). An earlier attempt 
to  use  a  LPS-binding  substance  to  treat  coliform  mastitis  was  made  by  Ziv  and  Schultze (1983), 
who tested polymyxin B, an antibiotic with the capacity to neutralize LPS, in an experimental LPS 
mastitis model. No significant beneficial effects were found when polymyxin B was administered 
shortly after LPS. In experimental E. coli mastitis model Pyörälä et al. (1994) compared 
intramammary treatment containing colistin, which also has a LPS neutralizing effect, with 
systemic trimethoprim-sulphonamide treatment or no-treatment, and found no significant 
differences in any clinical variables or the concentrations of LPS in the milk of infected quarters. 
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In our study (study IV) using intramammary Lf for treatment of E. coli mastitis, we decided to 
retain the advantage of a non-antibiotic approach and did not combine Lf with antimicrobials.  
Bovine  Lf  is  known  to  inhibit  the  growth  of  E. coli isolated from mastitis in vitro (Kutila et al. 
2003) and the disposition kinetics of Lf after intramammary administration were previously 
determined (Kutila et al., 2002). With a dose of 1g Lf, high concentrations of Lf are maintained in 
milk for several hours; the mean elimination half-life was 2.2 hours (Kutila et al., 2002). With an 
appropriate dose, Lf could support the clearance of bacteria from the udder and simultaneously 
block the effects of LPS by inhibiting the production of pro-inflammatory cytokines. Enrofloxacin 
was selected for our experiment as the positive control, because it was recommended for a treatment 
of coliform mastitis and approved for lactating cattle in the EU. For animal-welfare reasons, we 
decided to use supportive treatment for all cows. It would have been optimal to use an untreated 
control  group,  which  would  have  revealed  the  net  effect  of  the  intramammary  Lf  infusion.  In  the  
treatment of clinical E. coli mastitis, treatment is targeted at inhibiting bacterial growth, to reduce 
the exposure of the quarter to LPS. Furthermore, the effect of the LPS release should be neutralized 
to reduce the severity of the clinical signs (Erskine et al., 1991). 
 
We did not observed any significant differences in the clinical signs between cows treated with Lf 
and those receiving enrofloxacin. The NAGase activity, indicating inflammation in the quarter, 
decreased significantly faster in the group treated with enrofloxacin and a trend of faster elimination 
of bacteria from the challenged quarters was also seen.  
 
Zhang and co-workers (1999) studied a human Lf-derived 33-mer synthetic peptide (Lf-33) as a 
potential treatment for LPS-induced septic shock. In a mouse model, administration of Lf-33 
simultaneously with LPS significantly reduced mortality compared with LPS alone. In our study, 
LPS concentrations in milk were about 1400 times lower in relation to the number of bacteria in the 
Lf-treated cows than in the enrofloxacin-treated cows, which may indicate a LPS-neutralizing effect 
of the exogenous Lf. Another explanation could be that enrofloxacin killed bacteria more 
efficiently, resulting in a higher release of LPS from the bacterial cells and consequently a higher 
ratio of LPS to bacterial count. Three cows treated with Lf at the first challenge had lower bacterial 
counts at the second exposure compared with those treated with enrofloxacin. A rapid 
immunoresponse of the host may have eliminated most of the bacteria from the udder before the 
treatment with enrofloxacin was started at the second challenge. One explanation for the more rapid 
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immunoresponse may be the initial exposure to the bacteria during the first challenge or a possible 
immunostimulatory effect of Lf.  
 
Definite conclusions cannot be drawn as the study material was limited and an untreated control 
group was not included. Despite of the inconclusive results furnished by our experiment, we believe 
that Lf has potential as a non-antibiotic mastitis treatment of bovine mastitis. More studies using in 
vivo models are needed to explore this. Lactoferrin has antimicrobial activity against a variety 
species, and broad immunomodulatory properties, which make it interesting for treating 
inflammatory and infectious diseases.   
 
9.3. Virulence of mastitis E. coli isolates 
 
Major virulence factor groups of E. coli are  adhesins  and  toxins.  Adhesins,  such  as  Afa  adhesin,  
intimin, Dr adhesin,  P- and S-fimbriae,  CFAs, Saa,  OmpA, Curli,  aerobactin,  yersiniabactin,  Chu, 
flagellin and LPS, help bacteria to adhere, colonize and act as fitness factors (Kaper et al., 2004; 
Smith et al., 2007). Toxins, such as enterotoxins, Shiga toxin, Stx, CDT, Tsh, Stc, Map, IpaA, 
HlyA,  Ehx,  CNF1,  CNF2 and  Sta,  are  targeted  at  different  cellular  functions  and  act  in  cell  lysis  
(Kaper et al., 2004; Smith et al., 2007). The genes for virulence factors can be present in the 
genome of bacteria or in mobile genetic elements, including transposons, plasmids, bacteriophages 
and pathogenicity islands (Kaper et al., 2004; Smith et al., 2007). E. coli do not produce virulence 
factors continuously, but only when specific signals are received from the environment (China and 
Goffaux, 1999).  
 
Different virulence factor genes and their combinations were present in 39% of our E. coli isolates 
collected from our field study. Typically only one isolate represented each combination of genes, 
reflecting the high genotypic variability among E. coli isolates causing bovine mastitis. Our results 
agree with those from earlier studies, but the panel of the studied virulence factors differed among 
the studies (Nemeth et al., 1991; Nemeth et al., 1994; Kaipainen et al., 2002; Bean et al., 2004; 
Wenz et al., 2006). In our study the virulence factors detected, phylogeny groups or antimicrobial 
resistance traits of E. coli were not associated with the clinical signs of the cow at the acute stage of 
the disease, nor with the recovery from mastitis. These results are consistent with the previous 
findings, suggesting that severity of E. coli mastitis is not associated with any known specific 
virulence factor (Lehtolainen et al., 2003a; Wenz et al., 2006; Dyer et al., 2007). In our material, 
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over  60%  of  the  isolates  were  devoid  of  the  studied  virulence  genes.  In  an  earlier  Finnish  study  
(Kaipainen et al., 2002), approximately 50% of the isolates did not possess any virulence genes. In 
another study on E. coli isolates from bovine mastitis, 57.5% were without any virulence genes 
(Bean et al., 2004). The genes studied in those two studies differed from those included in our 
panel. In a recent study of Silva et al. (2009) on E. coli isolates from the uterus of puerperal dairy 
cows, only four virulence factor genes (hlyE, hlyA, iuc, and eaeA) in various combinations were 
detected in the isolates. None of the examined virulence genes was associated with infection in the 
uterus (Silva et al., 2009). 
 
The majority of the E. coli isolates in our study belonged to the phylogeny group A. Group A 
consists mainly of strains that are commensally orientated and not pathogenic for a healthy host 
(Clermont et al., 2000). They have been reported to have few virulence factors. Pathogenic 
intestinal E. coli strains occurred in groups A, B1 and D (Picard et al., 1999; Russo and Johnson, 
2000), whereas pathogenic extraintestinal E. coli belong mainly to groups B2 and D (Clermont et 
al., 2000). In the study of Silva et al. (2009), E.  coli isolates originating from the bovine uterus 
belonged mainly to phylogenetic groups A and B1, and had a low potential virulence. Dogan et al. 
(2006) reported in their study with three persistent and three transient E. coli mastitis strains, that all 
belonged to phylogeny group A and lacked virulence genes of invasive E. coli. This supports our 
conclusion that the mastitis-causing E. coli bacteria are typical commensals.  
 
In our field study the same genotype of E. coli was isolated three weeks post-treatment from 11% of 
quarters as was isolated initially from the same quarter, indicating persistence of the same strain of 
E. coli in the quarter. This figure is much lower than the 20.5% reported in a UK study by Bradley 
and Green (2001b), but close to 12.4% reported in an earlier Finnish study (Lehtolainen et al., 
2003a). The British study included only six herds compared with our 65 herds, which may have 
affected the results. In our study, post-treatment samples were stored frozen, which can influence 
growth of E. coli (Schukken et al., 1989) and may decrease the frequency of re-isolation. No 
bacterial feature – phylogeny group, virulence factor or resistance trait - was associated with 
persistence of the E. coli intramammary infection in the udder. Contradictory results were presented 
in a previous Finnish study of Lehtolainen et al. (2003a), where the genes cnf1, cnf2, sfaD and papC 
were significantly associated with re-isolation of E. coli post-treatment. In their study, the 
persistence of the same strain was not confirmed by PFGE. We found only three strains with 
virulence genes for CNF2 and none of them was persistent.  In our data P-fimbria was detected in 
16% and S-fimbria in 2% of the isolates and neither of them was linked to persistence of the 
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intramammary infection.  Recurrent E. coli mastitis has been reported to have a tendency towards 
milder clinical signs than seen in the non-recurrent cases, which was suggested to favour the 
intramammary infection becoming chronic (Bradley and Green, 2001). In the earlier Finnish study, 
no differences were found in the severity of clinical signs of intramammary infections, which 
remained persistent as compared with those that were eliminated (Lehtolainen et al., 2003a), in 
agreement with our findings.  
 
Commensal strains of E. coli commonly lack the specialized virulence traits that are present in 
pathogenic strains (Russo and Johnson, 2000). Dogan et al. (2006) found that E. coli isolated from 
persistent intramammary infection survived and also replicated intracellularly in vitro. However, 
intracellular multiplication of E. coli in the mammary epithelial cells has not yet been reported in 
vivo. Shpigel et al. (2008) suggested that E. coli associated with persistent bovine intramammary 
infection could have some unknown bacterial factors for pathogenity. Our results did not support 
their suggestion of a specific mammary-pathogenic E. coli.  Our  conclusion  was  that  mastitis-
causing E. coli bacteria,  at  least  in  this  study  material  (study  III),  appeared  to  be  typical  
commensals. However, we found one E. coli pulsotype  that  caused  persistent  mastitis  in  two  
individual cows at a 3 year interval in one herd. In the study of Blum et al. (2008), comprising one 
herd, isolates of E. coli were suggested to form a subset of the general environmental E. coli 
population. The authors speculated that these isolates could better multiply in the mammary gland 
and were genetically distinct from most environmental strains. It is possible that some E. coli strains 
could have some other mechanisms, not covered in the published studies, which influence their 
ability to cause mastitis, in particular persistent intramammary infections. One possible mechanism 
is suggested to be biofilm formation of E. coli bacteria in chronic or recurrent type of mastitis 
(Melchior et al., 2006). This ability of E. coli was not found to be associated with bovine uterine 
infections (Silva et al., 2009). More research is needed with new markers for virulence to further 
explore the existence of possible mammary pathogenic E. coli. 
 
Among the virulence factor genes detected in our study, only iucD was associated with 
antimicrobial resistance to streptomycin, ampicillin, sulfametoxazol and trimethoprim. The gene 
iucD codes for aerobactin, which is involved in the iron-chelating ability of E. coli and may be 
located either on a chromosome or on a plasmid, where also many of the antimicrobial resistance 
genes are reside (Bagg et al., 1987; Hirsh et al., 1993; Johnson et al., 2002). The gene iucD was also 
associated with iss (gene for increased resistance to serum), which might also be located on a 
plasmid (Johnson et al., 2002). Plasmids are major factors for the dissemination of both antibiotic 
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resistance and virulence determinants among bacterial populations. The presence of virulence and 
antibiotic resistance determinants in the same genetic element will produce co-selection of both 
types of determinant. For bacteria carrying those linked determinants, the selection of an infective 
population will evolve towards antibiotic resistance, and antibiotic selective pressure will select the 
virulence trait (Martínez and Baquero, 2002). In our study antimicrobial resistance traits of the E. 
coli isolates were not associated with any clinical variables or recovery from mastitis.  
 
In the present study (study III), 18.6% of E. coli isolates from mastitis were resistant to ampicillin, 
16.4% to streptomycin, 15.7% to tetracycline and 13.6% to sulfametoxazol. The proportions of 
resistance to the other antimicrobials were lower. Only one isolate showed resistance to 
ciprofloxacin.  The  prevalences  of  antimicrobial  resistances  of  E. coli isolated from mastitis seen 
here were higher than in the national resistance surveillance programme (FINRES-Vet 2005-2006), 
in  addition  20  %  of  our  material  were  multiresistent  as  compared  with  only  6  %  in  the  national  
surveillance data (FINRES-Vet 2005-2006). Our data originates from limited geographical area, 
which may partly explain the differences when compared to national data. In a Swedish report, in 
which the same cut-off values were used, resistance proportions of E. coli isolates were generally 
only half of those recorded for our material (Bengtsson et al., 2009). The most frequent resistance 
of mastitis E. coli isolates was found against antimicrobials used for years in dairy cows, including 
ampicillin,  streptomycin,  sulphonamide  and  tetracycline.  In  addition,  resistances  to  most  of  these  
antimicrobials often were associated, indicating that they appear in the same isolates, also seen by 
Lehtolainen et  al.  (2003b).  Resistances to the traditional antimicrobials of E. coli mastitis isolates 
found here were more numerous than reported in the Netherlands (MARAN 2007), but taking into 
account cut-offs of the Dutch study, the concentrations and the resistance figures were mainly 
similar to ours. Antimicrobial resistance can only be compared if the same cut-offs have been used 
(Schwarz et al., 2010). The cut-off values used in the resistance monitoring systems, e.g. for 
enrofloxacin,  can  differ  by  as  much as  3  dilution  steps,  from 0.25μg to  2  μg,  and  data  cannot  be  
compared (SVARM 2008; MARAN 2007). The development of antimicrobial resistance among E. 
coli isolated in animals has generally increased (White 2006). Resistance against fluoroquinolones 
is still rare among E. coli isolated from bovine mastitis, being only 0-2% (FINRES-Vet 2005-2006; 
MARAN 2007; AFFSA 2008). Resistance against fluoroquinolones among enterobacteria is caused 
by mutations in the gyrase or topoisomerase genes (Robicsek et al., 2006).  
 
In our material 1% of the isolates was resistant to ceftazidime, but none to ceftiofur. In other studies 
resistance of bovine E. coli isolates to third of fourth generations cephalosporins has also been low 
 70
(MARAN 2007; FINRES-Vet 2005-2006; Bengtsson et al., 2009). Resistance to cephalosporins in 
E. coli is primarily caused by production of extended spectrum beta-lactamases (ESBL) coding for 
resistance not only to aminopenicillins, but also to cephalosporins. Genes coding for ESBLs have 
been increasingly reported in Enterobacteria, including E. coli isolated from food producing 
animals (Batchelor et al., 2005; White 2006; SAGAM 2009), which is a reason for concern. 
Detection of the first E. coli isolates from bovine mastitis producing ESBL was recently reported 
(Locatelli et al., 2009). Resistance genes for fluoroquinolone resistance and production of ESBL are 
often encoded on plasmids or other mobile genetic elements and often linked to other resistance 
genes (Robicsek et al., 2006; White 2006; SAGAM 2009).  
 
Resistance among mastitis causing E. coli may reflect the general use of antimicrobials in the herd, 
as these bacteria are mostly commensals. The use of antimicrobials in the Finnish dairy herds has 
been strictly controlled and all antimicrobials are provided under veterinary prescription. Use of 
narrow-spectrum antimicrobials such as penicillin G is recommended, which should reduce the 
selection pressure to evolve resistance (Evira 2009). Routine antimicrobial treatment is not 
recommended for E. coli mastitis in Finland (Evira 2009).   
 
9.4. Prevention of E. coli mastitis 
 
The main principles to prevent mastitis and maintain good udder health are a comfortable, clean and 
dry environment for dairy cows, good-quality feeding and fresh drinking water, good milking 
hygiene, and proper herd management (Hogan and Smith, 2003; Pyörälä 2008; Corbett 2009). A 
contaminated environment is the main source of E. coli mastitis (Nemeth 1994; Lipman et al., 
1995). Keeping stalls and yards, cow traffic areas, and lying areas clean generally reduces 
contamination of the udder and consequently environmental mastitis (Hogan and Smith, 2003). Dry 
cow management and proper maintenance of calving units significantly affects the susceptibility of 
cows to puerperal mastitis. This is important because E. coli intramammary infections are most 
common and severe around calving and during early lactation (Bradley and Green, 2000; Green et 
al., 2007). Inadequate nutrition, pregnancy and stress can influence the immune system of the cow 
by depressing the function of immune cells (Lippolis et al., 2008). Feed should contain the 
recommended levels of vitamin and trace elements. Vitamins E and A, selenium, copper and zinc 
have a role in defense of the cow against intramammary infections (Godden et al., 2006).  
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Prophylactic immunization using vaccines has been used for preventing coliform mastitis. Vaccines 
based on the core antigen of coliform bacteria (E. coli J5), have been in use in the North America 
for two decades (Cullor et al., 1991; Wilson and Gonzàlez, 2003). This type of vaccine is now also 
available in the EU (EMA 2009). The common core vaccine is administered systemically at the 
drying-off and again 3 weeks before the calving date. The effect of vaccination lasts about 2.5 
months,  but  does  not  protect  the  cow  from  clinical  mastitis  (Wilson  et  al.,  2007a;  Wilson  et  al.,  
2007b). Smith et al. (1999) showed that subcutaneous combined with intramammary immunization 
with E. coli J5 bacterin produced enhanced antibody titers in milk and serum, but did not reduce 
clinical signs after subsequent challenge with E. coli. Vaccination does not reduce the incidence of 
clinical mastitis, but reduces clinical signs of coliform mastitis, culling, cow death and milk losses 
(Wilson et al. 2007a; Wilson et al. 2007b). The mechanism of action of J5 vaccine is still unclear 
(Wilson et al. 2007b). One hypothesis for the potential mechanism of action of E. coli vaccine is an 
enhanced PMN diapedesis caused by mammary gland hyper-responsiveness (Dosogne et al. 2002b). 
Recently it was suggested that the positive effect of E. coli vaccination is associated with a memory 
antibody response of IgG1 and IgG2 isotypes (Wilson 2007b). Iron regulated outer membrane 
protein E. coli vaccines have been investigated in vitro (Lin et al. 1999), but no practical 
applications have been developed. It can be concluded that the only current mastitis vaccines with 
evidence of clinical efficacy are the common core vaccines used against coliform mastitis. A 
decision on the use of vaccination against coliform mastitis should be made for each herd, based on 
the mastitis situation in the herd and a cost-benefit analysis. In Finland coliform mastitis is rarely 
such a problem that introduction of the vaccination program would be economical, as the herds are 
relatively small and are mostly housed in stanchion barns.  
  
Genetic engineering of the dairy cow has been proposed by several authors to increase host defense 
against mastitis (Bramley et al., 2001; Pyörälä 2002; Maga et al., 2005; Oliver 2005). Resistance of 
the cows to mastitis could be increased by improving the immune response through modifying 
genes or by transferring genes from the other organisms (Oliver 2005). The first published study on 
the transgenic approach to enhance mastitis resistance was a mouse model against staphylococcal 
intramammary infection (Kerr et al., 2001). In the first published bovine model (Wall et al., 2005), 
cows carrying a gene coding lysostaphin were shown to resist S. aureus intramammary infection. 
 
In this thesis (study V) we investigated whether expression of hLf in the bovine mammary gland 
would increase the resistance of dairy cows to E. coli mastitis. Our study was the first describing an 
experimentally induced mastitis model using rhLf-transgenic dairy cows. The high concentration of 
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Lf in the milk of the transgenic cows did not protect the udder from E. coli intramammary infection, 
and all of the cows became infected. No differences were noted in the bacterial growth, times to 
bacterial elimination, local signs, peak concentrations of LPS in the milk, or any of the milk or 
blood inflammatory parameters, except in concentrations of Hp and cortisol levels in the serum. 
However, the systemic signs were significantly milder in the transgenic group. 
 
Recombinant hLf present in milk of transgenic animals is structurally and functionally similar to 
natural hLf (Nuijens et al., 1993), but despite sequence homology, differences in their activity may 
exist, as has been shown for bovine and human lactoferricin (Farnaud et al., 2004). The human Lf 
gene is under the control of bovine αS1-casein promotor (Brink et al., 2000). During intramammary 
infection αS1-casein decreases in the milk, but the expression of casein does not change 
significantly (Schmitz et al., 2004), neither does the expression of rhLf. The regulation of bLf 
differs from that of the other milk proteins, such as casein (Schanbacher et al., 1993). The 
concentration of bLf in milk is related to the number of neutrophils in milk because bLf is released 
from the specific granules of neutrophils (Hagiwara et al., 2003). In mastitic milk, the differences 
were found in antibacterial activities of bLf compared with healthy milk (Komine et al., 2005). In 
our study (study V), the level of rhLf was relatively constant during intramammary infection, which 
suggests that rhLf may be largely independent of the regulation of bLf during the inflammation.  
 
Kutila et al. (2003) found that E. coli isolates, including our experimental strain, were inhibited by 
Lf at concentration of 1.67 mg/ml in vitro and the bacterial killing effect occurred at a relatively 
high initial concentration of bacteria (5000 cfu/ml). In our study (study V), bacterial counts in the 
milk of the groups did not differ significantly, which could mean that the level of Lf in milk was 
insufficient for a bacteriostatic effect, despite the susceptibility of the E. coli strain  to  Lf. The 
concentration  of  Lf  mRNA in  the  cisternal  region  and  in  ducts  near  the  teat  is  higher  than  in  the  
epithelial ducts of the mammary parenchyma and location may affect the prophylactic capacity of 
Lf against bacterial invasion via the teat (Molenaar et al., 1996).  
 
Part of the immunomodulatory function of Lf is to bind LPS and down-regulate LPS-induced 
cytokines (Legrand et al., 2004). Lf is one of the proteins with high-affinity LPS binding, but it does 
not completely neutralize LPS activity because lipid A can remain active even after a Lf-LPS-
complex has been formed (Na et al., 2004). Our finding of reduced clinical signs for transgenic 
animals may indicate that elevated Lf inhibited the activity of LPS to some extent, but not totally. 
Lf is also believed to act like LPS-binding protein during the inflammatory activation of 
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macrophages (Na et al., 2004) and may compete with LPS-binding protein (LBP) for binding to 
LPS (Legrand et al., 2005). The LPS-neutralizing activity of Lf may depend on the presence and 
concentration of other LPS-binding proteins. 
 
In studies of experimentally induced LPS and E. coli mastitis, the increase in concentrations of 
cortisol in the blood was temporary in cows with mild and moderate responses (Hirvonen et al., 
1999; Jackson et al., 1990), but remained elevated in cows with the most severe reaction (Hirvonen 
et al., 1999). In our study, concentration of cortisol in serum increased earlier and remained high for 
a longer time in the control cows than in the transgenic cows, indicating that the controls developed 
a stronger inflammatory reaction.  
 
The lower concentrations of acute phase proteins, SAA and Hp, in the transgenic cows indicated a 
milder response to infection. SAA and Hp peaked earlier in the milk than in the serum in both 
groups, which probably resulted from the rapid local production of these proteins in the mammary 
gland as described before (Hiss et al., 2004), and as recorded in study I. Haptoglobin may 
complement the actions of Lf (Hiss et al., 2004). It helps restrict the infection by limiting the free 
iron available for E. coli bacteria, which is also a function of Lf, by binding harmful molecules such 
as hemoglobin produced after tissue damage (Baumann et al., 1994). 
 
The rise of serum TNF-α reflects the severity of the systemic signs (Blum et al., 2000; Hirvonen et 
al., 1999). Concentrations of TNF-α were generally higher in the transgenic cows, but the difference 
between the groups was not significant. Lf may modulate immune responses by inhibiting cytokine 
activity and this inhibition has been shown to be concentration dependent (Crouch et al., 1992; 
Haversen et al., 2002). Blum et al. (2000) reported that peak TNF-α concentrations in plasma were 
up to 20-fold lower than maximal concentrations reached in milk in acute mastitis induced by E. 
coli infection and endotoxin. In our study, serum TNF-α concentration in the transgenic group was 
almost 100-fold and in the control group 30-fold lower than maximal concentrations in the milk, 
probably due the higher Lf concentrations and its LPS-neutralizing effect resulting inhibited TNF-α 
response in the milk of transgenic cows. 
 
The bovine hLf-transgenic model did not provide protection against E. coli mastitis in dairy cows, 
in contrast to lysostaphin-transgenic cows, which resisted intramammary S. aureus infection (Wall 
et al., 2005). The differences between these two infection models may partly explain the 
inconsistent results. The inflammatory response of the mammary gland to E. coli is characterized by 
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an acute rapid onset of infection, whereas S. aureus tends to cause slow-developing chronic 
infection (Bannermann et al., 2004). The protective effect of additional Lf in milk could be 
enhanced under natural conditions, where the infection generally develops more gradually. Lf 
reduced the severity of the inflammatory reaction, which could be seen in the systemic signs and in 
the serum cortisol and haptoglobin concentrations. However, Lf may not be a likely candidate for 
genetic engineering to enhance mastitis resistance of dairy cattle, but increasing the innate 
immunity of the dairy cows using such techniques cannot be completely dismissed. The ethical 
aspects of this kind of modification of the genome of the dairy cow need discussion as consumers 
have concerns regarding food produced via gene manipulation. It is more likely that specific genetic 
traits linked with mastitis resistance are identified (Griesbeck-Zilch et al., 2009; Alain et al., 2009) 
and used for breeding dairy cows to enhance their resistance against mastitis in the future.  
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10. CONCLUSIONS 
 
1. Two consecutive experimental E. coli intramammary infections in dairy cows 2 weeks apart 
caused a significant immunological carry-over effect. The interval between two 
experimental challenges should be longer than 2 weeks if the same cows are used in 
crossover trials. 
 
2. Systemic enrofloxacin treatment of acute clinical mastitis caused by E. coli was not more 
efficacious than supportive treatment only. 
 
3. Frequent milking at the acute stage of E. coli mastitis was beneficial and may reduce tissue 
damage in the udder. 
 
4. E. coli isolated in mastitis were mainly of commensal phylogeny type and had no specific 
virulence factors tested here related to clinical signs or persistence of the infection in the 
mammary gland. 
 
5. E. coli isolated from mastitis in southern Finland were susceptible to most antimicrobials 
tested. The highest prevalences of resistance were found for ampicillin, streptomycin, 
oxytetracycline and sulfametoxazol. 
 
6. Lactoferrin administred via the intramammary route was less efficacious than systemic 
enrofloxacin for treatment of experimental E. coli mastitis. 
 
 
7. hLf-transgenic dairy cows, expressing recombinant human lactoferrin in their milk, were not 
protected against experimental E. coli intramammary infection, but their response was 
milder as compared with that of normal cows.  
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